|

 

Microsoft word - 2013-06 pb cv.doc

CURRICULUM VITAE BSc PhD DSc (Med) DSc (hc) FRSE FFPH FRCPS (Glas) FRCP (Edin) FMedSci Knight's Cross of Order of Merit of Republic of Poland Fellow, National Academy of Scotland Fellow, Academy of Medical Science (United Kingdom) Honorary Member, Hungarian Academy of Science C: Users fourneraj Documents PB 2013-06 PB CV.doc CURRICULUM VITAE
Name: Peter
Place of Birth: Glasgow
Nationality:
Civil Status:
Married with three grown-up children. Languages
English (native) French (read, write and speak well) speak well and write minimally)
Education and Qualifications:
B.Sc. Statistics, University of Glasgow Ph.D. Faculty of Medicine, University of Glasgow FRSE Fellow of Royal Society of Edinburgh FFPH Fellow, Faculty of Public Health Medicine (United Kingdom) FRCPS(Glas) Fellow, Royal College of Physicians and Surgeons of Glasgow FMedSci Fellow, Academy Medical Sciences DSc (Med) Faculty of Medicine, University of Glasgow DSc (honoris causi) Faculty of Science, University of Aberdeen. FRCP (Edin) Fellow, Royal College of Physicians of Edinburgh LlD (honoris causi), University of Dundee.
Academic Appointments:
1974-77
Statistician, University Department of Medicine, Glasgow. , UK Statistician, West of Scotland Cancer Surveillance Unit, Glasgow, UK Senior Statistician, West of Scotland Cancer Surveillance Unit, Glasgow, UK. 1984-1987 Instructor and Assistant Professor, Departments of Biostatistics and Epidemiology, Harvard School of Public Health, Boston, USA Instructor and Assistant Professor, Division of Biostatistics and Epidemiology, Dana-Farber Cancer Institute, Boston, USA Senior Scientist, SEARCH Programme, Unit of Analytical Epidemiology, Research on Cancer, Lyon, France Head, SEARCH Programme, Unit of Analytical Epidemiology, International Agency for Research on Cancer, Lyon, France Chairman, Department of Epidemiology and Biostatistics, and Director, Division of Cancer Control, European Institute of Oncology, Milan, Italy. 2004-2008 Director, International Agency for Research on Cancer, Lyon, France. 2009- President, International Prevention Research Institute (Lyon, France) 1996 - 2005 Professor of Cancer Epidemiology, The University of Birmingham, UK Visiting Professor, University of Glasgow, United Kingdom 1996-2004 Professor, Postgraduate School of Pathology, University of Milan, Italy Professor of Cancer Prevention and Control, University of Oxford, UK. 1996-2003 Director, World Health Organisation Collaborative Centre for Statistical Modelling in Epidemiology of Chronic Diseases. Honorary Professor, University of Dundee, United Kingdom C: Users fourneraj Documents PB 2013-06 PB CV.doc Professor Adjunct, Yale University, New Haven, USA
Employment History
1974-1977. I was appointed Research Assistant (Statistician) in the Department of Medicine in the University of Glasgow in 1974. My work involved interaction with clinicians and other researchers on statistical aspects of their research work. 1977-1980. In 1977, I was appointed Statistician at the West of Scotland Cancer Surveillance Unit located at Ruchill Hospital in Glasgow. The work involved providing statistical support to the West of Scotland Cancer Registry, to the newly formed West of Scotland Oncological Association and to clinicians and other scientists engaged in cancer research and clinical trials. 1980-1984. I was promoted to Senior Statistician in the West of Scotland Cancer Surveillance Unit. The areas of responsibility remained the same but there was an additional level of responsibility. I supervised the work of the registry clerical and administrative staff (6 wte positions) and one junior statistician. During this period of employment, I had a sabbatical when I was awarded an IARC Research Training Fellowship to spend one year at the International Agency for Research on Cancer (Lyon, France) and four months at Harvard School of Public Health (Boston, Massachusetts). 1984-1987. I was appointed initially as Instructor and then as Assistant Professor in the Departments of Epidemiology and Biostatistics at Harvard School of Public Health (Boston, Massachusetts). I had a simultaneously appointment as Instructor and then Assistant Professor in the Department of Biostatistics and Epidemiology at the Dana-Farber Cancer Institute (Boston, Massachusetts). I provided epidemiological support at the Dana-Farber and was involved in research and teaching activities at the School of Public of Health. I supervised my first two doctoral students. I was given a initial leave of absence to take up a position at the International Agency for Research on Cancer (Lyon, France). I left to take up a higher position and to work in an international environment. 1986-1990. I was appointed as Senior Scientist to lead the SEARCH (Surveillance of Environmental Aspects Related to Cancer in Humans) programme of the International Agency for Research on Cancer (IARC). This is part of the World Health Organisation and based in Lyon, France. I had a staff of 6 scientists and an in-house research budget of 350,000 dollars per annum. The programme attracted research funding for participating research teams in the participating countries. 1990-1991. I was promoted Head, SEARCH Programme at the IARC. The duties remained the same but the programme had expanded and there were more studies to supervise and coordinate. I left to take up a challenging job as the first employee of the newly created European Institute of Oncology. 1991-2003. I was appointed as the Director of the Division of Epidemiology and Biostatistics at the European Institute of Oncology. This was a newly created Institute which opened its hospital operation in 1994 (with 260 beds). I headed a Research Group which initially comprised three Senior Scientists, six technical assistants and two secretaries. The initial core funding for the research programme was approximately 1 million Euros. This built up to an C: Users fourneraj Documents PB 2013-06 PB CV.doc international programme with five Senior Scientists, ten PhD/MSc assistants, five post-docs, 3-5 PhD students, an administrative assistant and two personal assistants. The final core budget was approximately 2 million Euros and we had over 2 million Euros in Research Grants when I left. I left on being elected Director of the IARC by the Member States. 2004-2008. I was elected Director of the International Agency for Research on Cancer (World Health Organisation) at the meeting of the Governing Council in May 2003 and took up post on 1st January 2004. This one of eight elected positions within the World Health Organisation and I was the first United Kingdom citizen to hold such a position within WHO. I was responsible for 350 personnel and the biennial budget was grown from 35.8 million dollars (for 2002-2003) to 44.7 million dollars (for 2008-2009). External research funding grew from an average of 10 million US dollars per annum before my arrival to an average of 23 million dollars per annum in the first four years (such funding was 34 million dollars in 2007). Five new participating States were introduced, enlarging the Agency from 16 to 21 members. 2009 to present. After completion of my mandate at IARC, I created the International Prevention Research Institute which is initially based in Lyon. This is a new concept in biomedical research combining a thorough, high-level, academic approach coupled with a practical focus on providing clear information about evidence-based clinical, epidemiological and prevention strategies. iPRI serves as an independent authoritative source of advice on critical risk issues and as a high-level training centre in all aspects of Prevention research. An academic partnership has been created with the University of Dundee and IPRI-Dundee has been formally established. IPRI comprises 8 partners initially and has a budget estimated to be 6-8 million Euros in 2010. With an outstanding faculty and international expertise, our mission is to bring the available excellence in scientific method to clarify critical issues in disease determination and prevention in order to contribute to the improvement in health of populations worldwide.
Major Research Contributions

I have had a productive research career in Epidemiology and I am a recognised leader in the
global cancer control movement. In the latter role I have proved to be an efficient catalyst for
important international collaborations particularly in low- and medium-income countries and, in particularly, providing a forum for collaboration among National Cancer Institutes. In my personal research, I have been active in several areas and we will highlight three below where hmy work has made a difference to disease prevention and clinical management.
In the area of Tobacco Control, I was a Member of the European Cancer Advisory Board. In
this role I was able to develop the proposal for a European Union Tobacco Directive with its scientific justification. I worked closely as scientific advisor to the Commissioner, Mr David Byrne, and to the European Commission on the European Tobacco Contents Directive which was voted into law by the European Parliament in 2002. This European-wide law restricted the tar, nicotine and CO2 contents of cigarettes which could be sold in Europe, which banned the use of descriptors such a Light and Low and legislated for stronger health warnings and graphic pictures on packets of cigarettes sold throughout Europe. This was the first European law on Tobacco and paved the way for subsequent anti-tobacco legislation in the European Union and its Member States. Notably, I worked closely with several National Governments on the introduction of bans on smoking in bars, restaurants and public places. C: Users fourneraj Documents PB 2013-06 PB CV.doc
I was the driving force behind the development of the four versions of the European Code
Against Cancer, in 1988, 1993, 2003 and 2009. This process involved a Europe wide
consultation from experts from a wide variety of fields and developed a series of recommendations to the general public to reduce the incidence and mortality of cancer. The European Code Against Cancer (the first and second version) was the basis of the Europe Against Cancer Programme target to reduce the number of cancer deaths in the European Union between 1985 and 2000. Although mortality rates were rising when the plan was launched in 1985, a 9.5% reduction in the number of cancer deaths expected in 2000 was achieved, preventing 98,000 cancer deaths each year.
In my work in Urological Disease, I have applied an evidence-based approach to modifying
the impact on treatment choices and outcome. My meta-analysis of the Phase III clinical trials
of finasteride demonstrated that this drug was effective only in men with enlarged prostates. I was also able to demonstrate that finasteride reduced the risk of Acute Urinary Retention. I performed subsequent meta-analysis which demonstrated the effectiveness of terasozin and permixon, and the efficacy of Trans Urethral Needle Ablation (TUNA) in Benign Prostatic Hyperplasia. These findings have influenced clinical practice in benign prostatic hyperplasia in helping clarify what is the right treatment for a particular patient and this is reflected currently in international treatment guidelines. In addition, my work in Urology also included a pooled analysis of the world's three leading Dialysis Registries, involving over 900,000 patients, dialysed but not transplanted, followed up for cancer; the demonstration that testicular cancer mortality rates were reduced following the implementation of effective therapy which, unfortunately, was not the case in countries of Central and Eastern Europe. My research work has greatly influenced treatment outcomes and, together with my work in cancer control, has undoubtedly led to the prevention of many deaths.
External Appointments
1987-1996- Visiting Lecturer, Harvard School of Public Health, Boston. Honorary Lecturer, University Department of Surgery and Department of Epidemiology and Community Medicine, University College Dublin, Ireland. Honorary Senior Lecturer, Eastman Institute of Dental Health Science, London. 1996-2002 Adjunct Professor, Department of Epidemiology and Family Medicine, University of Pittsburgh, Pittsburgh, United States. 1999-2003 Honorary Professor, National School of Public Health Carlos III, Madrid, Spain 1999-2003 Scientific Advisor in Prevention and Control, ICRF, London 1999-2002 Chairman, and Control, ICRF, London. 1999-2002 Adjunct Member, Memorial Sloan Kettering Cancer Institute, New York. 2003- Director Emeritus, European Institute of Oncology (Milan, Italy) Advisor, National Cancer Center of Korea Affiliate, R. Samuel McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Canada. External Member, University of Otaga, Dunedin, New Zealand. C: Users fourneraj Documents PB 2013-06 PB CV.doc Professional Qualifications
1974 Fellow, Royal Statistical Society 1979 Fellow, Institute of Statisticians 1993 Chartered Statistician, Royal Statistical Society
Honours, and Awards Won in Competition:
1981 Travel Fellowship, British Association for Research on Cancer
1981 International Cancer Research Technology Transfer (ICRETT) Fellowship (UICC) 1981 Cancer Research Training Fellowship , International Agency for Research on Cancer 1981 Training Award Greater Glasgow Health Board 1981 Travel Fellowship, Churchill Scholarship Trust for Scotland 1982 Research Training Fellowship International Agency for Research on Cancer (declined) 1994 Premio La Madonnina - City of Milan, Italy 1995 Addlemen Visiting Professor, University of Toronto, Canada. 1997 Visiting Professor, Institute of Urology, Moscow State University, Moscow, Russia 1998- Visiting Professor, Department of Urology, University of Innsbruck, Innsbruck, Austria. 1996 Honorary Member, Argentine Medical Association. 2000 Knight's Cross of Order of Merit of Republic of Poland 2000 Fellow of Royal Society of Edinburgh. 2002 Award from President of Israel for Lifetime Contribution to Cancer Research, on Occasion of 50th Anniversary of Israel Cancer Association, Jerusalem, 2002. 2003 Honorary Member, Hungarian Cancer Society. 2003 Honorary Member, European Society for Therapeutic Radiology and Oncology (ESTRO) 2006 Award of Honorary Doctor of Science by University of Aberdeen. 2006 Elected Fellow of Academy of Medical Science. 2006 Elected Fellow of Royal College of Physicians of Edinburgh. 2006 Elected Full member of ESMO (first non-Medical Oncologist elected to Full Membership). 2008 Gold Award of the Health Promotion Foundation of Poland. 2010 Elected Honorary Member of Hungarian Academy of Science. 2012 Award of Honorary Doctor of Laws by University of Dundee.
Invited Eponymous Lectures
Royal College of Physicians of Canada Lecturer, Canadian Urological Association, Canada (1998) Europa Donna Lecture, Second European Breast Cancer Conference, Barcelona, Spain (2001) Adelman Lecture, Princess Margaret Hospital, Toronto, Canada (2000) Aneurin Bevin NHS Lecture, British Association of Cancer Research, Leeds (2002) Kodak Lecture, British Association for Mammographic Screening, Edinburgh (2002) Giullian Lecture, Italian Sociaty of Urology, Venice (2002) Millins Symposium Lecture, Royal College of Surgeons of Ireland, Dublin, Ireland (2002) BJU Int lecture, British Association of Urological Surgeons, Harrogate, UK (2003) Davidson Lecture, Royal College of Physicians of Edinburgh (Aberdeen, 2008) Annual Acta Oncologica Lecture 2008, Danish Oncological Society (Vejle, 2008) C: Users fourneraj Documents PB 2013-06 PB CV.doc Plenary Lectures at international meetings including the American Society for Clinical Oncology; the American Association for Cancer Research; the European Association of Urology, the European Respiratory Society, the European Breast Cancer Meeting, the European Association for Cancer Research, the European Society for Mastology, the European Cardiology Association, the European Society for Medical Oncology, the European Cancer and Clinical Oncology meeting, the European Society for Radiology and Therapeutics in Oncology, Canadian Urological Association, Asian Urological Association, Princess Takamatsu Symposium, Singapore Medical Association, Malayasian Urological Association, Australasian Urological Association, Yugoslavian Urological Association, Greek Urological Association, Danish Oncological Society, Polish Urological Society, Israel Cancer Society, Luxembourg Cancer Society, Hong Kong Medical Society, Chinese Association of Urology, Cancer Prevention Association of Thailand, Hungarian Oncological Society, Portugese Urological Association, Italian Association for Clinical Oncology, German Association for Medical Documentation, International Union Against Cancer, Finnish Cancer Society, Luxembourg Medical Society, South African Urological Association, Portuguese Oncological Society, British Association for Cancer Research, Hungarian Urological Association and Czechoslovakian Urological Association. Invited lectures at Scientific Meetings organised in Portugal, Spain, Italy, France, Germany, Austria, Belgium, Netherlands, United Kingdom, Ireland, Greece, Finland, Norway, Sweden, Denmark, Luxembourg, Slovenia, Slovakia, Czech Republic, Switzerland, Yugoslavia, Hungary, Poland, Lithuania, Russian Federation, United States, Cuba, Canada, Brazil, Argentine, Singapore, Malaya, Korea, China, Hong Kong, Japan, India, Sri Lanka, Thailand, Israel, Abu Dhabi, Australia, Jordan and New Zealand.
Major Committee Assignments
Secretary, Epidemiology and Prevention Branch, EORTC, Brussels Scientific Advisory Committee (Breur Committee), EORTC, Brussels 1989-97 Chairman, and Prevention Branch, European Society of Mastology 1989-03 International Prostate Health Council 1990-91 Professorial Appointments Committee, Faculty of Medicine, University of Lausanne Treasurer and Member of Executive Board, European Society of Mastology 1992-97 Chairman, and Prevention Branch, EORTC. Secretary, Scientific Advisory Committee (Breur Committee), EORTC. Scientific Advisory Board, European School of Oncology, Milan Scientific Committee, ECCO8 Meeting (1996) Chairman, Committee to revise European Code Against Cancer. Chairman, Committee to prepare EuropeanTobacco Control recommendations. Member, Cancer Advisory Board of European Commission. Chairman, Scientific Committee, European Commisssion Tobacco Fund. Scientific Committee, Institut Gustav-Roussy (Villejuif, France) Chairman, European Commission Expert Committee Cancer Plan, 2000-4 1998-2002 Scientific Advisory Committee, ICRF, London 1999-2002 Chairman, Committee, European Tobacco Fund, EC. 2000-2003 Scientific Center for Cancer Detection and Prevention, St Gallen. 2001-2003 Italian Representative, European Commission Advisory Committee on Tobacco. C: Users fourneraj Documents PB 2013-06 PB CV.doc Member, Italian National Oncological Commission, Ministry of Health, Italy. Member, Electromagnetic Fields Commission, Ministry of Health, Italy Chairman, Commission to Investigate Clustering of Leukaemia in Children, around Radio Vaticana Transmitter, Ministry of Health, Italy. Member, CEO Advisory Committeee, American Cancer Society. Member, General Motors Prize (Mott) Committee Member, International Affairs Committee, AACR Member, Multidisciplinary Oncology Committee, ESMO. 2008-2010 Member, International Affairs Committee, ASCO. Member, International Advisory Panel, Strathclyde University. Member, Steering Committee Pink Ribbon Red Ribbon Initiative Co-chair. Targets and Metrics Committee, PRRR.
Editorial Boards

Editorships:
Journal of Epidemiology and Biostatistics (with Carlo La Vecchia and Alec Walker)(1995-2003) European Journal of Cancer (1990-1994).

Associate Editorships,
Oncology and Haematology Literature Service (1993-98), Annals of Oncology (1999-) British Journal of Urology International (2002-). Onkologie (2010 - )
Editorial Board Member,
Cancer Causes and Control (1990-1994), Swiss Journal of Social and Preventive Medicine (1990- ), British Journal of Cancer (1990-1997), Prospectives (1990-99), BPH Observer (1990- 99), The Breast (1991-97), Oral Oncology (1991- ), European R and D Database (1993-98), Lung Cancer (1995- ), Journal of Radiation Therapy (1996- ), European Cancer News (1996- 98), Journal of Gynecologic Oncology (1996- ), Annals of Oncology (1996-), URO (Portuguese Journal of Urology) (1996-), Breast Cancer Online (1999- ), Lancet (2003-), Nature Clinical Practice Urology (2004-), Molecular Oncology (2006-), Hematologia (2010-). C: Users fourneraj Documents PB 2013-06 PB CV.doc Selected Publications of Peter Boyle
1. Cairns, J. and Boyle, P. Cancer chemotherapy. Science, 1983, 220, 252-256.
2. Kerr, D.J., Burt, A.D., Brewin, T.B. and Boyle, P. Divergence between mortality and
incidence rates of thyroid cancer in Scotland. Lancet, 1985, ii (8447), 149. 3. Macfarlane, G.J., Boyle, P. and Scully, C. (letter) Rising mortality from cancer of the
tongue in Young Scottish Males. Lancet 1987, ii:912. 4. Scully, C., Boyle, P. and Prime, S. Oral Cancer (Editorial). Lancet ii (8658), 1989:
5. Boyle, P., Maisonneuve, P., and Kaye, S.B. Testicular Cancer in Central Europe. Lancet
6. Lowenfels AB, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, Dimagno EP, Andren-Sandberg A, Domellof L, Maisonneuve P, Di Francesco V, Lohr-Happe A, Krag E, Melton LJ, Pitchumoni CS, Wynn PS and Boyle, P. Pancreatitis and the risk of Pancreatic
Cancer. New Eng.J.Med. 1993, 328 20:1433-1437
7. Boyle P. The Hazards of Passive and Active Smoking. New Engl.J.Med. 1993, 328:1708-
8. Boyle P, La Vecchia C, Negri E, Lucchini F and Levi F. Trends in diet-related cancers in
Japan: a conundrum? (Letter). Lancet 1993, 342:752 9. Boyle, P, Macfarlane GJ and Scully C . Oral Cancer: necessity for Prevention Strategies
(Editorial). Lancet 1993, 342:1129 10. Boyle P. The Hazards of Active and Passive Smoking. Letter to the Editor. N.Engl.J.Med.
1993, 329 (21): 1581 11. Zakelj M. and Boyle P. Breast Cancer Detection and Oral Contraceptive use in Slovenia
(letter). Lancet, 1994, 343: 1166-1167 12. Neglia J, FitzSimmons S, Maisonneuve P, Schoni M, Schoni-Affolter F, Corey M, Lowenfels A, Boyle P, Dozor A, Durie P. The Risk of Cancer Among Patients with Cystic Fibrosis. N
Engl J Med 1995, 332:494-499 13. Plesko I, Ondrus D, Boyle P. Testicular cancer incidence and mortality in Slovakia, 1968-
1990. Lancet 1996, 347, 900-901 14. Buccianti G, Ravasi B, Cresseri D, Maisonneuve P, Boyle P, Locatelli F. Cancer in
patients on renal replacement therapy in Lombardy, Italy. (Letter). Lancet, 1996; 347 C: Users fourneraj Documents PB 2013-06 PB CV.doc 15. Collaborative Group on Hormonal Factors in Breast Cancer (includes P Boyle). Breast
cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53.297 women with breast cancer and 100.239 women without breast cancer from 54 epidemiological studies. Lancet, 1996, 347: 1713-1727. 16. Boyle P. Global burden of cancer. Lancet (suppl), 1997, 349: 23-26.
17. Osborne M., Boyle P., Lipkin M. Cancer Prevention. Lancet, 1997, 349 (suppl): 27-30.
18. Becker N., Boyle P. Decline in mortality from testicular Cancer in West Germany after
re-unification. Letter) Lancet, 350: 744. 19. Gray N., Boyle P. Attacks on tobacco Industry (Letter). Lancet, 350: 890, 1997.
20. Collaborative Group on Hormonal Factors in Breast Cancer (includes P Boyle), Breast
Cancer and Hormone Replacement Therapy. Lancet, 1997, 350: 1047-1059. 21. Franklyn J.A., Maisonneuve P., Sheppard M.C., Betteridge J., Boyle P. Mortality after the
Treatment of Hyperthyroidism with Radioactive Iodine. New Engl J Med, 338: 712-8, 1998. 22. Boyle P., Horton R., Radda G., Sharp D., Veronesi U., Walker A.M. Open debate on
HRT. Lancet, 352: 836, 1998 23. Veronesi U., Maisonneuve P., Costa A., Sacchini V., Maltoni C., Robertson C., Rotmensz N., Boyle P. on behalf of the Italian Tamoxifen Study Group. Prevention of Breast
cancer with Tamoxifen. The Italian Randomised Trial among Hysterectomised women.
The Lancet, 352: 93-97, 1998. 24. Gray N., Boyle P., Zatonski W. Tar concentrations in cigarettes and carcinogen content.
Lancet, 352:787-788, 1998. 25. Autier P., Boyle P., J.F.Dore'. Letter: Sorting the hype from the facts in melanoma.
Lancet, 352: 738-739, 1998. 26. Boyle P. Expanding on epidemiology's first principles. Book review: Modern
Epidemiology by K. Rothman et al. Lancet, 352:1635-1636, 1998 27. Veronesi U., Maisonneuve P., Costa A., Rotmensz N., Boyle P. Drop-outs in Tamoxifen
Prevention Trials. Lancet, 353:244,1999 28. Franklyn J.A., Maisonneuve P., Sheppard M., Betteridge J., Boyle P. Cancer Incidence
and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. The Lancet, 353: 2111-2115, 1999 C: Users fourneraj Documents PB 2013-06 PB CV.doc 29. Maisonneuve P., Agodoa L., Gellert R., Stewart J.H., Buccianti G., Lowenfels A.B., Wolfe R.A., Jones E., Disney A., Briggs D., McCredie M., Boyle P. Cancer in end stage renal
disease patients undergoing dialysis: results from an international collaborative study.
Lancet, 1999; 354: 93-96. 30. Clinical Synthesis Panel on HRT. Clinical Synthesis Conference on Hormonal Replacement Therapy. Lancet 1999; 354: 152-156. 31. Gray N., Zatonski W., Boyle P. Regulation of carcinogens in cigarettes. The Lancet, 18
(354): 1036, 1999 32. Boyle P, Horton R, Walker AM, Sharp D and Delmas P. Clinical Synthesis Meeting on
Osteoporosis. Lancet 1999; Nov 13;354(9191):1664. 33. Levi F, La Vecchia C, Boyle P, Lucchini F, Negri E. Western and eastern European trends
in testicular cancer mortality. Lancet 2001 Jun 9;3 57 (9271):1853-4. 34. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and
cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001 Sep 15;358(9285):861-5 35. Collaborative Group on Hormonal Factors in Breast Cancer (includes P Boyle). Familial
breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001 Oct 27;358(9291):1389-99 36. Veronesi U, Maisonneuve P., Sacchini V., Rotmensz N., Boyle P Tamoxifen for breast
cancer among hysterectomised women. Lancet 2002; 359: 1122-4. 37. Collaborative Group on Hormonal Factors in Breast Cancer (includes P Boyle). Breast
cancer and breast feeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002 Jul 20;360(9328):187-95. 38. Veronesi U, Maisonneuve P, Rotmensz N and Boyle P. Tamoxifen for breast cancer in
hysterectomised women (Letter). Lancet 2002; 360 (9347): 1784-1785. 39. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S and Boyle P. Overview of
main Outcomes in Breast Cancer Prevention Trials. Lancet 2003; 361: 296-300. 40. Pastorino U, Bellomi M, Landoni C, DE Fiori E, Arnaldi P, Picchio M, Pelosi G, Boyle P and
Fazio F. Early lung-cancer detection with spiral CT and positron emission tomography: two years results. Lancet 2003; 362: 593-597. 41. Gray N and Boyle P. The Future of the Nicotine Addiction Market. (Commentary) Lancet
2003 Sep 13;362(9387):845-6. C: Users fourneraj Documents PB 2013-06 PB CV.doc 42. Collaborative Group on Hormonal Factors in Breast Cancer (includes P Boyle). Breast
cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83 000 women with breast cancer from 16 countries. Lancet 2004; 363: 1007- 43. Veronesi U, Boyle P, Goldhirsch A, Orrechia R and Viale G. Seminar on Breast Cancer.
Lancet. 2005 May 365 (9472):1727-41. 44. Boyle P, Ariyaratne M, Bartelink H, Baselga J, Berns A, Brawley OW, Burns H, Davidov
M, Dinshaw K, Dresler C, Eggermont AM, Gajurel D, Gordina G, Gray N, Kakizoe T, Karki BS, Kásler M, Kerr DJ, Khayat D, Kiselev A, Khuhaprema T, Klocker H, Levshin V, Martin- Moreno JM, McVie JG, Mendelsohn J, Napalkov NP, Ngoma TA, Park JG, Philip T, Pötschke-Langer M, Poudal HN, Rajan B, Ringborg U, Rodger A, Seffrin JR, Shanta V, Shrestha MM, Thomas R, Tursz T, de Valeriola D, Veronesi U, Wiestler OD, Zaridze D, Zatonski W and Zeng YX. Curbing tobacco's toll starts with the professionals: World No Tobacco Day. The Lancet (11th June) 2005; 365: 1990-1992 45. Boyle P, Ariyaratne MA, Barrington R, Bartelink H, Bartsch G, Berns A, de Valeriola D,
Dinshaw KA, Eggermont AM, Gray N, Kakizoe T, Karki BS, Kaslar M, Kerr DJ, Khayat D, Khuhaprema T, Kim IH, Martin-Moreno J, McVie G, Park JG, Philip T, Ringborg U, Rodger A, Seffrin JR, Semiglazov V, Soo KC, Sun YT, Thomas R, Tursz T, Veronesi U, Wiestler O, Yoo KY, Zatonski W and Zhao P. Tobacco: deadly in any form or disguise. Lancet. 2006 May 27;367(9524):1710-2.
46. Boyle P. The Globalisation of Cancer. Lancet 2006; 368: 629-630
47. Boyle P. Book Review: Conspiracy theories of cancer, Lancet 2007; 370: 1751
48. Hainaut P and Boyle P. Curbing the Liver Cancer Epidemic in Africa. Lancet 2008;
371(9610): 367-368. C: Users fourneraj Documents PB 2013-06 PB CV.doc PUBLICATIONS 1

Kemp, I.W., Boyle, P., Smans, M. and Muir, C.S. "Cancer Incidence in Scotland: Atlas and
Epidemiological Perspective". IARC Scientific Publication No. 72, IARC, Lyon (1985).
Boyle, P., Muir, C.S., Grundmann, E. (Eds.). "Cancer Mapping". Recent Results in Cancer
Research, Vol. 114, Springer-Verlag, Heidelberg, 1989
Zatonski, W., Boyle P. and Tcyznski, J. (eds). "Cancer Epidemiology: Vital Statistics through
Prevention". Interpresse, Warsaw, 1990.

Katsouyanni, K., Kogevinas, M., Dontas, N., Maisonneuve, P., Boyle, P. and Trichopoulos, D.
Cancer Mortality in Greece, 1960-1985. Hellenic Cancer Society, Athens, Greece, 1990.

Veronesi, U., Boyle, P., Ciatto, J., Goldhirsch, A., van der Schueren, E., Pastorino, U.
Textbooks for General Practitioners, II. Breast Cancer. Springer-Verlag, Heidelberg, 1990.
Levi, F., La Vecchia, C., Negri, E., Randriamiharisoa, A. and Boyle, P. Le cancer en l'an 2000:
Les modèles statistiques âge/période/cohorte pour la projection de la mortalité cancéreuse en Suisse. Ligue Suisse Contre le Cancer, Berne, 1991
Macfarlane GJ, Maisonneuve P and Boyle P. SEARCH: A computer Package to assist the
statistical analysis of Case-Control Studies. IARC Technical Report, IARC, Lyon, 1991
Smans, M., Boyle, P. and Muir, C.S. (eds) "Cancer Mortality Atlas of EEC'. IARC Scientific
Publication No 107, IARC, Lyon, 1993.
Black RJ, Macfarlane GJ, Maisonneuve P, and Boyle P. Cancer Incidence and Mortality in
Scotland 1960-89. Information and Statistics Division National Health Service in Scotland / Cancer Research Campaign / The Government Statistical Service / European Institute of Oncology , 1995.
Zatonski W, Smans M, Tyczynski J, Boyle P. "Cancer Mortality Atlas in Central Europe". IARC
Scientific Publications No. 134. IARC, Lyon , 1996.
Alexander, F.E. and Boyle, P. (Eds) "Statistical Methods in Cancer Research: IV Analysis of
disease clustering". IARC, Lyon 1996.

Griffiths K, Aldercreutz H, Boyle P, Denis L, Morton M. "Nutrition and Cancer", ISIS Medical
Communications. Oxford, 1996.

Kirby R, Roehrborn C, McConnell J, Fitzpatrick J and Boyle P (Eds)."Textbook of Benign
Prostatic Hyperplasia", ISIS Medical Communications, Oxford, 1996.
Aapro M., Audisio R., Boyle P., McCaffrey-Boyle D., Corner J., Monfardini S., Redmond K.
(eds.) Cancer in the Elderly, a nursing and medical perspective. ESO Scientific Updates 2, Amsterdam: Elsevier, 1997. C: Users fourneraj Documents PB 2013-06 PB CV.doc Kirby R., McConnell J.D., Fitzpatrick J.M., Roehrborn C.G., Boyle P. Ipertrofia Prostatica
Benigna Vol. I- II, Milano: UTET Periodici, 1997.
Boyle P., La Vecchia C., Walker AM. (eds). FIGO Annual Report on the Results of Treatment in
Gynaecological Cancer, 24th Volume Statements of results obtained in patients treated in 1993-
1995, Journal of Epidemiology and Biostatistics, Vol 6. Oxford: Isis Medical Communications, 2001.
McArdle CS, Kerr DJ and Boyle P (Eds). Monographs in Oncology. Volume I. Colorectal Cancer,
ISIS Medical Publications, Oxford (2000).
Kirby RS, McConnell JD, Fitzpatrick J, Roehrborn CG, Wyllie M and Boyle P (Eds). Therapeutic Treatment for Benign Prostatic Hyperplasia. Informa Healthcare, London (2005)
Boyle P, Gray N, Zatonski W, Henningfield J and Seffrin J. Tobacco: Public Health Disaster of
the Twentieth Century. Oxford University Press, Oxford (2004)
Boyle P and Smans M. Cancer Mortality Atlas of European Union, 1993-1997. IARC Press, IARC
(Lyon) (2008)
Curado MP, Edwards BK, Shin HR, Storm HH, Heanue M, Ferlay J and Boyle P. eds. Cancer
incidence in five continents. Vol. IX (9). Lyon, France: IARC Press, 2007. (IARC Scientific
publications no. 160.)
Boyle P and Levin B (Eds). World Cancer Report 2008. IARC, Lyon (2008)

Boyle P and Levin (Eds). Dünya Kanser Raporu 2008. IARC, Lyon (2008)

Boyle P, Gray N, Zatonski W, Henningfield J and Seffrin J. Tobacco: Science, Policy and Public
Health. 2nd Edition. Oxford University Press, Oxford (2010)

Zheng T, Boffetta P and Boyle P. Epidemiology and Biostatistics. iPRI Scientific Publication No
1, iPRI, Lyon, France
Boyle P, Boffetta P, Zatonski W, Rehm J, Burns HJG and Lowenfels A. Alcohol: Science, Policy
and Public Health. Oxford University Press, Oxford (in preparation).
Boyle P, Brawley O, Burns HJG, Adebawomo C, Sullivan R and Milburn A. Deprivation: Science,
Policy and Public Health. Oxford University Press, Oxford (in preparation). C: Users fourneraj Documents PB 2013-06 PB CV.doc Publications 2
Scientific Articles (excluding published abstracts)
Boyle P., Parbrook G.D. The inter-relation of personality and post-operative factors. Brit. J. Anaesth., 49: 259-264, 1977. Ramsay L.E., Boyle P., Ramsay, M.H. Factors influencing serum potassium in treated hypertension. Quarterly J. Med., 46, 401-409,1977. Parbrook E.O., Parbrook G.D. Boyle P. Comparison of synchronised and manual use of audio tape slide programmes. Anaesthesia., 32: 614-619, 1977. Nichols G., Ramsay L.E., Boyle P. The Elag-Koln automatic blood pressure recorder - a clinical appraisal. Brit. Heart J., 29: 795-801, 1977. Winchester J.F., Kellett R.J., Boddy P., Boyle P., Dargie H.J., Mahaffey H.J., Mahaffey K.E., Ward D.M., Kennedy A.C. Metolazone and bendroflumethazide in hypertension: physiologic and metabolic observations. Clin. Pharmacol. Ther., 28: 611-618, 1980. Stephen K.W., Kirkwood M., Boyle P., Young K.C., Gillespie F.C., Campbell D. Fissure sealing with nuva-seal and alpha-seal: two year data. J. Dentistry, 9: 53-57, 1981. Stephen K.W., Boyle I.T., Campbell D., MacNee S., Fyffe J.A., Jenkins A.S., Boyle P. A four-year double-blind fluoridated school milk study in a vitamin-D deficient area. Brit. Dent. J., 151: 287-292, 1981. Scully C., Eckersall P.D., Emond R.T.D., Boyle P., Beeley J. Serum alpha-amylase isozymes in mumps: estimation of salivary and pancreatic isozymes by isoelectric focusing. Clinica. Chimica. Acta., 113: 281-291, 1981. McInnes G.T., Quigley E.M.M., Boyle P. Alcohol withdrawal and blood pressure. Scot. Med. J., 26: 176-177, 1981. 10. Ferguson M.M., Carter J.C., Boyle P., McKay-Hart D., Lindsay R. Oral symptoms related to the female climacteric. J. Roy. Soc. Med., 74: 492-498, 1981. 11. Scully C, Boyle P.Nucleic acid-metabolising enzymes as markers in oral squamous carcinoma. IRCS Med. Sc., 9: 542-543, 1981. 12. Scully C., Spandidos D., Ward-Booth P., Boyle P., MacGregor I. Serum alkaline deoxyribonuclease in oral cancer and premalignant lesions. Biomedicine, 35: 179-180, 13. Mills P.R., Spooner R.J., Russell R.I., Boyle P., MacSween R.N.M. Serum glutamate dehydrogenase as a marker of hepatocyte necrosis in alcoholic liver disease. Brit. Med. J., 283: 754-755, 1981. C: Users fourneraj Documents PB 2013-06 PB CV.doc 14. Boyle P., Scully C. Changing morbidity and mortality from oral cancer in Scotland. IRCS Med. Sci., 9: 883, 1981. 15. Scully C., Barkus T., Boyle P., MacGregor I., Ward-Booth P. Immune complexes in oral cancer. IRCS Med. Sci., 9: 872, 1981. 16. Robertson A.G., Boyle P., Yosef H.M., Gillis C.R., Flatman G.E. Cancer of the larynx in West of Scotland. A review of the results and a consideration of new therapeutic approaches. Am. J. Clin. Oncol. (CTT), 5: 527-533, 1982. 17. Mills P.R., Boyle P., Quigley E.M.M., MacSween R.N.M., Watkinson G. Primary biliary cirrhosis. An increase in the incidence of associated extrahepatic malignant neoplasm? J. Clin. Path., 35: 541-543, 1982. 18. Boyle P., Robertson A.G., Gillis C.R., Flatman G.E., Scully, C. Epidemiology of laryngeal cancer in Scotland. IRCS Med. Sci., 10: 61-62, 1982. 19. Scully C., Boyle P. Beta-2 micro-globulin in Lichen Planus. J. Dent. Res., 61, 758-760, 20. Boyle P., Scully C. Epidemiological aspects of oral cancer. Acta Stomatologica Internationalia, 3: 193-200, 1982. 21. Ridley W.J., Jackson P., Stewart J.H., Boyle P. Role of the ante-natal radiography in the management of breech deliveries. Brit. J. Obs. Gynecol., 89: 342-347, 1982. 22. Scully C., Barkus T., Boyle P., McGregor I., Ward-Booth P. Circulating immune complexes detected by binding of radio labelled protein A in patients with oral cancer and oral premalignant lesions. J. Clin. Lab. Immunol., 8, 113-115, 1982. 23. Scully C., Boyle P., Yap P.L. Immunoglobulins G, M, A, D and E in Behcet's syndrome. Clinica Chimica Acta., 120: 237-242, 1982. 24. Scully C., Eglin R.P., Ward-Booth P., McGregor I.A., Boyle P. Human oral squamous cell carcinoma: evidence for RNA complementary to herpes simplex virus DNA. IRCS Med. Sci., 10: 531-532 1982. 25. Mackay A., Boyle P., Brown J.J., Forrest H., Graham A.G., Lever A.F., Robertson J.I.S., Semple P.F. The decision on surgery in renal artery stenosis. Quarterly J. Med., 52: 363-381, 1983. 26. Scully C., Yap P.L., Boyle P. IgD and IgE concentrations in patients with recurrent apthous stomatitis. Arch. Dermatol., 119, 31-34, 1983. 27. Scully C., Boyle P. Oral cancer: new immunological observations. Acta. Stomatologica Internationalia., 4: 17-19, 1983. C: Users fourneraj Documents PB 2013-06 PB CV.doc 28. Scully C., Boyle P. Screening for medical problems in dentistry: 1. Reliability of a self- administered questionnaire. Comm. Dent. Oral Epidemiol., 11:105-108, 1983. 29. Boyle P., Day N.E., Magnus K. Mathematical modelling of malignant melanoma trends in Norway, 1953-1978, Am. J. Epidemiol., 118:887-896, 1983. 30. Boyle P., Scully C., Smans M., Robertson A.G. Lip cancer mortality in Great Britain. IRCS Med. Sci., 11:178-179, 1983. 31. Cairns J., Boyle P. Cancer chemotherapy. Science, 220:252-256, 1983. 32. Boyle P., Soukop M., Scully C., Robertson A.G., Burns H.J.G., Gillis C.R. Improving prognosis of Hodgkin's disease in Scotland. IRCS Med. Sci., 11,:754-755, 1983. 33. Boyle P., Zaridze D.G. Colorectal cancer as a disease of the environment. Ecol. Dis., 2:241-248, 1983. 34. Stephen K.W., Boyle I.T., Campbell D., McNee S., Boyle P. A five-year double-blind fluoridated milk study in Scottish school children. Comm. Dent. Oral Epidemiol., 223-229, 1984. 35. Zaridze D.G., Boyle P., Smans M. International trends in prostatic cancer. Int. J. Cancer, 33:223-230, 1984. 36. Cowans B., Burns H.J.G., Boyle P. Ledingham I.M. The relative prognostic value of lactate and haemodynamic measurements in early shock. Anaesthesia, 39:750-755, 1984. 37. Cunningham D., Soukop M., McArdle C., Carter D.C., Smyth J., Allen S.G., Kaye, S.B., Sangster, G., Calman, K.C., Hutcheon, A. Boyle, P. Advanced gastric cancer: experience in Scotland using 5-fluoruracil, adriamycin and mytomycin-C. Brit. J. Surg., 71:673-676, 1984. 38. Galloway D.J., Boyle P., Davidson P.M., George W.D. Electro-analgesia following abdominal surgery: a clinical assessment. Surgery, Gynaecology and Obstetrics, 159:453-456, 1984. 39. Gillis C.R., Hole D.J., Hawthorne V., Boyle P. The effect of environmental tobacco smoking in two urban communities in western Scotland. Eur. J. Res. Dis. (supp), 65:121-126, 1984. 40. Galloway D.J., Burns H.J.G., Bear H., Boyle P., Jarrett F., George W.D. Colorectal cancer in young adults. Clin. Oncol., 10:205-211, 1984. 41. Ferguson M.M., Carter J., Boyle P. An epidemiological study of factors associated with recurrent aphthae in women. J. Oral Med., 39:212-217, 1984. 42. Robertson A.G., McGregor I.A., Flatman G.E., Soutar D.S., Boyle P. The role of radical surgery and post-operative radiotherapy in the management of intra-oral carcinoma. Brit. J. Plastic Surg., 29:314-320, 1985. C: Users fourneraj Documents PB 2013-06 PB CV.doc 43. Zaridze D.G., Kuvshinov J.P., Matiakin E., Polakov B.I., Boyle P., Blettner M. Chemoprevention of oral and esophageal cancer in Uzbekistan, USSR. NCI Monograph, Fourth Pacific Basin Symposium on Epidemiology, Bethesda, NCI, 259-262, 1985. 44. Boyle P., Zaridze D.G., Smans M. Descriptive epidemiology of colorectal cancer. Int. J. Cancer., 36:9-18, 1985. 45. Burt A.D., Kerr D.J., Brown I.L., Boyle P. Lymphoid and epitelial markers in small cell anaplastic thyroid tumours. J. Clin. Path., 38:893-896, 1985. 46. McCall D.R., Watkins T.R., Stephen K.W., MacFarlane G.J., Boyle P. APF gel application: further intra-oral loss and distribution studies. Brit. Dent. J., 159: 82-84, 1985. 47. Goudie B.M., Burt A.D., Boyle P., MacFarlane G.J., Birnie G.G., Mills P.R., Gillis C.R., Watkinson G., MacSween R.N.M. Breast cancer in women with primary biliary cirrhosis. Brit. Med. J., 291(6509), 1597-1598, 1985. 48. Kerr D.J., Burt A.D., Brewin T.B., Boyle P. Divergence between mortality and incidence rates of thyroid cancer in Scotland. Lancet, ii (8447):149, 1985. 49. Nichols R.J., Galloway D.J., Mason A.Y., Boyle P. Clinical local staging of rectal cancer. Brit. J. Surg., 72:51-52, 1985. 50. Yeung Laiwah A.C., MacPhee G.J.A., Boyle P., Moore M., Goldberg A. Autonomic neuropathy in acute intermittent porphyria. Neurosurg. Psychiatry, 48 (10):1025-1030, 1985. 51. Goudie B.M., Burt A.D., Boyle P., MacFarlane G.J., Birnie G.G., Gillis C.R., MacSween R.N.M., Watkinson G. Breast cancer in women with primary biliary cirrhosis. Br. Med. J., 292(6516): 52. Robertson A.G., MacGregor I.A., Soutar D.S., Ferguson M.M., Flatman G.E., Boyle, P. Post-operative radiotherapy in the management of advanced intra-oral cancers. Clin. Radiol., 37: 173-178 1986. 53. Robertson C., Boyle P. Age, period and cohort models: the use of individual records. Statistics in Medicine, 5: 527-538, 1986. 54. Kerr D.J., Burt A.D., Boyle P., Macfarlane G.J., Storer A.M., Brewin T.B. Prognostic Factors in Thyroid Tumours. Brit. J. Cancer, 54: 475-482, 1986. 55. Galloway D.J., Owen, R.W., Jarrett F., Boyle P., Hill M.J., George, W.D. Experimental colorectal cancer: the relationship of diet and faecal bile acid concentration to tumour induction. Brit. J. Surgery, 73: 233-237, 1986. 56. Katsouyani K., Trichopoulos D., Boyle P., Xirouchaki E., Trichopoulou A., Lisseos B., Vasilaros S. MacMahon B.Diet and Breast Cancer: A case-control study in Greece. Int. J. Cancer 38:815-820, 1986. C: Users fourneraj Documents PB 2013-06 PB CV.doc 57. Boyle P., Kaye S.B., Robertson A.G. Improving prognosis of testicular cancer in Scotland. ICRS Med. Sci., 14: 976-977, 1986. 58. Freer C.B., Boyle P., Ryan M. A study of attendance patterns in general practice over three years. Health Bull., 44: 78-80, 1986. 59. Boyle P., Robertson C. Statistical modelling of lung cancer and laryngeal cancer incidence data in Scotland, 1960-1979. Amer. J. Epidem., 125: 731-744, 1987. 60. Boyle P., Robertson C. Breast Cancer and Colon Cancer Incidence in Females in Scotland, 1960-84. J. Natl. Cancer Inst., 79:1175-1179, 1987. 61. Galloway D.J., Jarrett F., Boyle P., Carr C., Indran M., Owen R.W., George W.D. Morphological and cell kinetic effects of dietary manipulation during colorectal carcinogenesis. GUT, 28: 754-763, 1987. 62. Macfarlane G.J., Boyle P., Scully C. Rising mortality from cancer of the tongue in Young Scottish Males. (letter), Lancet ii: 912, 1987. 63. Robertson A.G., Boyle P., Deuchars F., Robertson C. Carcinoma of the Larynx. J. Surg. Oncol., 35: 217-222, 1987. 64. Zaridze D.G., Boyle P. Cancer of the prostate: epidemiology and aetiology. Brit. J. Urology, 59: 493-503, 1987. 65. Boyle P., Kaye S.B., Robertson A.G. Changes in Testicular Cancer in Scotland. Eur. J. Clin. Oncol., 23(6): 827-830, 1987. 66. Boyle P., Robertson C. Age-period-cohort modelling of malignant melanoma incidence in Scotland, 1960-1984. Amer. J. Epidem. 126: 766, 1987. 67. Goddard M.J., Krewski D., Boyle P. SEARCH - A Programme of IARC. Chronic Disease in Canada 9(2): 31-34, 1987. 68. Katsouyani K., Willett W., Trichopoulos D., Boyle P., Trichopoulou A., Vasilaros S., Papadiamantis J., MacMahon B. Risk of breast cancer among Greek women in relation to nutrient intake. Cancer 61: 181-185, 1988. 69. Robertson J., Boyle P., Imrie C.W. Patients with ampullary carcinoma are prone to other malignant tumours. Brit. J. Cancer 58: 216-28, 1988. 70. Boyle P., Soukop M., Scully C., Robertson A.G., Burns H.J.G, Gillis C.R. Improving prognosis of Hodgkin's Disease in Scotland. Eur. J. Cancer. Clin. Oncol. 24: 229-234, 1988. 71. Gillis C.R., Hole D.J., Boyle P. Cigarette smoking and male lung cancer in an area of very high incidence: report of a case-control study in the West of Scotland. J. Epid. Comm. Health. 42(1): 38-43, 1988. C: Users fourneraj Documents PB 2013-06 PB CV.doc 72. Boyle P., Leake R.E. Progress in Understanding Breast Cancer: Epidemiologic and Biologic Interactions. Breast Cancer Res. Treat. 11: 91-112, 1988. 73. Boyle P., Robertson C. Re: Statistical Modelling of Cancer Data. Am J. Epid. 129: 225-226, 74. Cuzick J., Boyle, P. Trends in Cervix Cancer Mortality. Cancer Surveys 7(3): 417-439, 1988. 75. Goudie B.M., Burt A.D., Macfarlane G.J., Boyle P., Gillis C.R., Watkinson G. Risk factors and Prognosis in Primary Biliary Cirrhosis. Amer. J. Gastroenterology 84: 713-720, 1989. 76. La Vecchia C., Boyle P., Cislaghi C., Decarli A., Negri, E. Descriptive Epidemiology of Hodgkin's Disease in Italy. Tumori, 75:401-405, 1989. 77. Boyle P. Breast Cancer - Do Dietary Factors Matter? Update 38 (7): 725-726,810, 1989. 78. Boyle P., Hsieh C.C., Maisonneuve P., La Vecchia C., Macfarlane G.J., Trichopoulos D., Walker A.M. Epidemiology of Pancreas Cancer. Int. J. Pancreatology, 5 (4):327-346, 1989. 79. Mack T., Boyle, P., Pour P. Pancreas Cancer: Integration of Epidemiology and Laboratory. Int. J. Pancreatology 5(4): 4-9, 1989. 80. Scully C., Boyle P., Prime S. Oral Cancer (Editorial). Lancet ii (8658): 311-312, 1989. 81. Mack T., Boyle P., Pour P. M. Summary of the Second Meeting of the International Pancreatic Cancer Study Group (IPCSG) Int. Journ of Pancreatology, 5:387-389, 1989. 82. La Vecchia C., Negri E., Boyle P. Reproductive Factors and Breast Cancer: An Overview. Soz. Praeventivmed 34: 101-107, 1989. 83. La Vecchia C., Negri E., Boyle P. Alcohol and Breast Cancer: Update from an Italian case-control study. Eur. J. Cancer and Clin. Oncol., 25:1711-1717, 1989 84. Levi F., Maisonneuve P., Filiberti R, La Vecchia C., Boyle P. Patterns of Cancer Incidence and Mortality in Europe. Swiss J. Preventive and Social Medicine Supp. 2: 1-84, 1989. 85. Boyle P., Macfarlane G.J., Maisonneuve P., Zheng T., Scully C., Tedesco B. Epidemiology of Mouth Cancer in 1989: a review. J. Roy. Soc. Med. 83: 724-730, 1990. 86. La Vecchia C., Boyle P., Cislaghi C., Decarli A., Negri E. Descriptive Epidemiology of Cancers of the Upper Digestive and Respiratory Tract in Italy. Rev. Epi. Sante Publ., 38:271-273, 1990. 87. La Vecchia C., Bruzzi P., Boyle P. Some further consideration on the role of oral contraceptives in breast carcinogenesis. Tumori, 76:220-224, 1990. 88. La Vecchia C., Negri E., d'Avanzo B., Ferraroni M., Gramenzi A., Savoldelli R., Boyle P., Franceschi S. Medical history, diet and pancreatic cancer. Oncology, 47:463-466, 1990. C: Users fourneraj Documents PB 2013-06 PB CV.doc 89. Kaye S.B., Boyle P. The Impact of Chemotherapy in Germ-cell Tumours. Cancer Surveys 8: 90. Negri E., La Vecchia C., Levi F., Decarli A., Boyle P. The Application of Age-Period and Cohort Models to predict Swiss Cancer Mortality. J. Cancer Res. Clin. Oncol., 116:207-214, 91. Parazzini F., La Vecchia C., Negri E., Bruzzi P., Palli D., Boyle P. Anthropometric Variables and Risk of Breast Cancer. Int. J. Cancer, 45:397-402, 1990. 92. Levi F., Maisonneuve P., Boyle P., Filiberti R., La Vecchia C. Incidence and Mortality of Tumours in Europe. Epidemiol.Prev., 12:56-62, 1990 93. Negri E., La Vecchia C., Decarli A., Boyle P. Projections of Mortality from Major Cancer Sites in Italy. Tumori, 76:420-428, 1990. 94. La Vecchia C., Negri E., Parazzini F., Boyle P., D'Avanzo B., Levi F., Gentile A., Franceschi S. Height and cancer risk in a network of case-control studies from Northern Italy. Int. J. Cancer, 45, 275-279, 1990. 95. La Vecchia C., Negri E., D'Avanzo B., Boyle P. Reported Alcohol Intake and Symptomatic Gallstones (letter to Editor). New Engl. J. Med., 322, 473 , 1990. 96. Boyle P., Tomatis L. Cancer Mortality in Italy. Tumori, 76:85-86, 1990. 97. Moller H., Boyle P., Maisonneuve P., La Vecchia C., Jensen O.M. Changing mortality of male oesophageal cancer in Denmark and other European countries in relation to increasing levels of alcohol consumption. Cancer Caus. Control, 1: 173-181, 1990. 98. La Vecchia C., Negri E., D'Avanzo B., Franceschi S., Decarli A., Boyle, P. Dietary Indicators of Laryngeal Cancer Risk. Cancer Research, 50: 4497-4500, 1990. 99. Boyle P. Breast Cancer and Dietary Factors (Editorial). Hospital Update, 16:11-15, 1990. 100.Boyle P., Maisonneuve P., Kaye S.B. Testicular Cancer in Central Europe. Lancet, 335:1033, 101.D'Avanzo B., Negri E., La Vecchia C., Gramenzi A., Bianchi C., Franceschi S., Boyle, P. Cigarette Smoking and Bladder Cancer. Eur. J. Cancer, 26 (6):714-718, 1990. 102.Bouchardy C., Clavel F., La Vecchia C., Raymond L., Boyle P. Alcohol, Beer and Cancer of the Pancreas. Int. J. Cancer, 45: 842-846, 1990. 103.La Vecchia C., Franceschi S., Bruzzi P., Parazzini F., Boyle, P. The relationship between oral contraceptive use, cancer and vascular disease. Drug Safety 5 (6): 436-446, 1990. C: Users fourneraj Documents PB 2013-06 PB CV.doc 104.Boyle P., Zheng T., Macfarlane G.J., McGinn R., Maisonneuve P., La Vecchia C., Scully C. Recent advances in the etiology and epidemiology of Head and Neck Cancer. Current Opinion in Oncology, 2: 539-545, 1990. 105.Levi F., Ollyo J.B., La Vecchia C., Boyle P., Monnier P., Savary M. The Consumption of Tobacco, Alcohol and the Risk of Adenocarcinoma in Barrett's Oesophagus, Int. J. Cancer, 45: 852-854, 1990. 106.La Vecchia C., Negri E., D'Avanzo B., Boyle P., Franceschi S. Medical History and Primary Liver Cancer. Cancer Res. 50: 6274-6277, 1990. 107.Negri, E., La Vecchia C., D'Avanzo B., Gentile A., Boyle P., Franceschi S. Salt Preference and Risk of Gastrointestinal Cancers. Nutr. Cancer, 14: 227-232, 1990. 108.Franceschi S., La Vecchia C., Negri E., Parazzini F., Boyle P. Breast cancer risk and history of selected medical conditions linked with female hormones. Eur. J. Cancer 26: 781-786, 1990. 109.Oishi K., Okada K., Yoshida O., Yamabe H., Ohno Y., Hayes R.B., Schroeder F.H., Boyle P. A case-control study of prostatic cancer in Kyoto, Japan: sexual risk factors. The Prostate, 17: 269-279, 1990. 110.Boyle P. SEARCH Programme of the IARC (Editorial). Eur. J. Cancer 26 (5): 547-549, 1990. 111.Ad Hoc Working Group (Boyle P., Cardis E., Coleman M.P., Saracci R., Ahlbom A., Feychting M. and 18 others). Extremely low-frequency electric and magnetic fields and risk of human cancer. Bioelectromagnetics, 11: 91-99, 1990. 112.Zheng T., Boyle P., Hu H.F., Duan J., Ma L., Shiu L., Niu S., MacMahon B. Tobacco smoking, alcohol consumption and risk of oral cancer: a case-control study in Beijing, People's Republic of China. Cancer Causes and Control, 1: 173-180, 1990. 113.Zheng T., Boyle P., Hu J., Duan P., Jiang D., Ma L., Shui L., Niu S., Scully C., MacMahon B. Dentition, oral hygiene and risk of oral cancer: a case-control study in Beijing, People's Republic of China. Cancer Causes and Control, 1: 235-242, 1990. 114.Adami H.-O., Adams G.E.D., Boyle P., Ewertz M., Lee N.C., Lund E., Miller A.B., Olsson H., Steel M., Tricholoulos D., Tulinius H. Breast Cancer Etiology. Int. J. Cancer suppl., 5: 22-39, 115.Boyle P. Cigarette Smoking and Pancreas Cancer. Tobacco Alert (October), 2: 8-12, 1990. 116.Boyle P., Maisonneuve P., Saracci R., Muir C.S. Is the Increased Incidence of Primary Malignant Brain Tumours in the Elderly Real? (Editorial). J. Natl. Cancer Inst., 82: 1594-1597, 1990. 117.Katsouyanni K., Kogevinas M., Dontas N., Maisonneuve P., Boyle P., Trichopoulos D. Cancer Mortality in Greece, 1960-1985. Hellenic Cancer Society, Athens, Greece, 1990. C: Users fourneraj Documents PB 2013-06 PB CV.doc 118.Boyle P. Epidemiology of Benign Prostatic Hyperplasia. Prospectives, 1(3): 1-4, 1990. 119.Muir C.S., Boyle P. The Burden of Cancer in Europe. Eur. J. Cancer, 26: 1111-1113, 1990. 120.Hsieh C.C., Maisonneuve P., Boyle P., Macfarlane G.J., Robertson C. Analysis of quantitative data by quantiles in epidemiologic studies: classification according to cases, noncases or all subjects. Epidemiology, 2: 137-140, 1991. 121.Baghurst P.A., McMichael A.J., Slavotnik A.H., Baghurst K.I., Walker A.M., Boyle P.A case-control study of diet and cancer of the pancreas. Amer. J. Epidem., 134: 167-179, 122.Levi F., La Vecchia C., Randriamiharisoa A., Boyle P. Cancer mortality in young adults in Switzerland, 1951-1989. J.Cancer Res.Clin.Oncol., 117:497-501, 1991. 123.La Vecchia C., Levi F., Franceschi S., Boyle P. Assessment of screening for cancer. Journal of Technicology Assessment in Health Care, 7 (3):275-285, 1991. 124.La Vecchia C., Negri E., D'Avanzo B., Boyle P. Risk factors for gallstone disease requiring surgery. Int. J. Epidemiol., 20: 209-215, 1991. 125.Boyle P., McGinn R., Maisonneuve P., La Vecchia C. Epidemiology of Benign Prostatic Hyperplasia: Present Knowledge and Studies Needed. Eur.Urology, 20(suppl 2): 3-10, 1991. 126.La Vecchia C., Negri E., D'Avanzo B., Franceschi S., Boyle P. Dairy products and the risk of prostatic cancer. Oncology 48: 406-410, 1991. 127.Zatonski W., Przwoniak K., Howe G.R., Maisonneuve P., Walker A.M., Boyle P. Nutritional Factors and Pancreatic Cancer: A Case-control study from South-West Poland. Int. J. Cancer, 48: 390-394, 1991. 128.La Vecchia C., Negri E., D'Avanzo B., Boyle P., Franceschi S.Dietary indicators of oral and pharyngeal cancer. Int. J. Epidemiol., 20: 39-44, 1991. 129.D'Avanzo B., Negri E., Gramenzi A., Franceschi S., Parazzini F., Boyle P., La Vecchia C. Fats in seasoning and breast cancer risk: an Italian case-control study. Eur. J. Cancer, 27: 130.Ghadirian P., Simard A., Baillargeon J., Maisonneuve P., Boyle P. Nutritional Factors and Pancreatic Cancer in the Francophone Community in Montreal, Canada. Int. J. Cancer, 47: 1-6, 1991. 131.La Vecchia C., Boyle P., Franceschi S., Levi F., Maisonneuve P., Negri E., Lucchini F., Smans M. Smoking and Cancer with Emphasis on Europe, Eur. J. Cancer, 27: 94-104, 1991. 132.Zheng T., Boyle P. A case-control study of oral cancer in Beijing. Tobacco Alert, (July C: Users fourneraj Documents PB 2013-06 PB CV.doc 133.Boyle P. Cancer Incidence Registration. Eur. J. Cancer, 27: 112-113, 1991. 134.Cockett AT, Aso Y., Denis L., Khoury S., Barry MJ., Boyle P., (and 17 others). Recommendations du Comite' de Consensus de l'OMS concernant l'evaluation diagnostique de l'HPB. Progress en Urologie 1:957-972, 1991. 135.Gray J.M.B., Beard K., Lawson DH., Kemp I., Trotter P., Boyle P. Long-term Phenothiazine use and Breast and Pancreatic Cancer in Scottish In-patients. Pharmaceut.Med., 5:107-112, 1991. 136.Bueno de Mesquita B., Maisonneuve P., Moerman C.J., Runia S., Boyle P. Life-time history of smoking and exocrine carcinoma of the pancreas. A population-based case-control study in the Netherlands. Int.J.Cancer, 49:816-822, 1991. 137.Katsouyanni K., Boyle P., Trichopoulos D. Diet and urine estrogens among postmenopausal women. Oncology, 48:490-494, 1991. 138.De Vries N., Boyle P. Alcohol verhoogt risico voor Kanker van de Bovenste Voedsel- en lucht wegen. Kanker (the Netherlands), 15:240-241, 1991. 139.La Vecchia C., Levi F., Lucchini F., Kaye S.B., Boyle P. Hodgkin's Disease Mortality in Europe. Brit. J. Cancer, 64: 723-734, 1991. 140.Negri E., Franceschi S., Tzonou A., Booth M., La Vecchia C., Parazzini F., Beral V., Boyle P., Trichopoulos D. Pooled analysis of three European case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer. Int. J. Cancer, 49:50-56, 1991. 141.Ghadirian P., Boyle P., Simard A., Baillargeon J., Maisonneuve P., Perret C. Reported Family Aggregation of Pancreatic Cancer within a population based case-control study in the Francophone Community in Montreal, Canada. Int. J.Pancreatol., 10:183-196, 1991. 142.La Vecchia C., Levi F., Lucchini F., Evstifeeva T., Boyle P. Cancer Mortality in the Union of Soviet Socialist Republics (USSR), 1986-88. Int. J. Cancer, 49:678-683, 1991. 143.La Vecchia C., Negri E., Franceschi S., D'Avanzo B., Boyle P. Tea consumption and cancer risk. Nutrition and Cancer, 17:27-32, 1992. 144.Howe G.R., Ghadirian P., Bueno de Mesquita H.B., Zatonski W., Baghurst P.A., Miller A.B., Simard A., Baillargeon J., de Waard F., Przewozniak K., McMichael A.J., Hsieh C.C., Maisonneuve P., Boyle P., Walker A.M. A collaborative case-control study of nutrient intake and pancreatic cancer within the SEARCH Programme. Int.J.Cancer, 51 : 365-372, 1992. 145.Zheng T., Mayne S.T., Boyle P., Holford T.R., Flannery J.T. Epidemiology of Non-Hodgkin's Lymphoma in Connecticut, 1935-1988. Cancer, 70:840-849, 1992. 146.La Vecchia C., Lucchini F., Negri E., Boyle P., Maisonneuve P., Levi F. Trends of Cancer Mortality in Europe, 1955-89. I. Digestive Sites. Eur. J. Cancer, 28:132-235, 1992. C: Users fourneraj Documents PB 2013-06 PB CV.doc 147.La Vecchia C., Lucchini F., Negri E., Boyle P., Maisonneuve P., Levi F. Trends of Cancer Mortality in Europe, 1955-89. II Respiratory tract, bone, connective and soft tissue sarcomas, and skin. Eur. J. Cancer, 28:514-599, 1992. 148.La Vecchia C., Lucchini F., Negri E., Boyle P., Maisonneuve P., Levi F. Trends of Cancer Mortality in Europe, 1955-89. III Breast and Genital Sites. Eur. J. Cancer, 28:927-998, 1992. 149.La Vecchia C., Lucchini F., Negri E. Boyle P., Maisonneuve P., Levi F. Trends in Cancer Mortality in Europe, 1955-89. IV, Urinary tract, eye, brain and nerves, and thyroid. Eur.J.Cancer, 28:1210-1281, 1992. 150.La Vecchia C., Lucchini F., Negri E., Boyle P., Maisonneuve P., Levi F. Trends in Cancer Mortality in Europe, 1955-89 V Lymphohaemopoietic and all cancers. Eur.J.Cancer, 28:1509-1581, 1992. 151.Boyle P. Trends in Cancer Mortality in Europe (editorial). Eur.J.Cancer, 28:7-8, 1992. 152.Boyle P. In-My-View: Population Studies in Benign Prostatic Hyperplasia. Prospectives 2:5- 153.Boyle P., Macfarlane G.J., Zheng T., Maisonneuve P., Evstifeeva T., Scully C. Recent Advances in Epidemiology of Head and Neck Cancer. Current Opinion in Oncology, 4:471- 154.Zatonski W., La Vecchia C., Przewozniak K., Maisonneuve P., Lowenfels A.B., Boyle P. Risk factors for Gallbladder Cancer. A Polish case-control study. International Journal of Cancer, 51:707-711, 1992. 155.Boyle P. Book Review: Nutrients and Cancer Prevention, Eur.J.Cancer, 28: 236 - 237, 1992. 156.Scully C., Boyle P., Tedesco B. The recognition and diagnosis of cancer arising in the mouth. Postgraduate Doctor, 15:134-141, 1992. 157.Boyle P. Cancer: An Increasing Research Priority. Medicographia, 14:3-9, 1992. 158.Boyle P. Some remarks on the Epidemiology of Benign Prostatic Hyperplasia. European Urology Today, 2:10-11, 1992. 159.Boyle P. Book Review: "Human Carcinogen Exposure: Biomonitoring and Risk Assessment". Eur. J.Cancer, 28A:1929, 1992. 160.Boyle P. Editorial: Epidemiology in Central and Eastern Europe. Epidemiology, 3:391-394, 161.Boyle P. Screening for Prostatic Diseases. Prospectives, 3:1-5, 1992. C: Users fourneraj Documents PB 2013-06 PB CV.doc 162.Boyle P. Book Review: Observation and Inference: An Introduction to the Methods of Epidemiology. Cancer Causes Control, 3:183, 1992. 163.Bueno de Mesquita H.B., Maisonneuve P., Moerman C.J., Runia S., Boyle P. Lifetime consumption of alcoholic beverages, tea and coffee and exocrine carcinoma of the pancreas: A population-based case- control study in the Netherlands. Int.J.Cancer, 50:514-522, 1992. 164.Levi F., La Vecchia C., Lucchini F., Negri E., Boyle P. Patterns of Childhood Cancer. Incidence and Mortality in Europe. Eur. J. Cancer, 28A:2028-2049, 1992. 165.Macfarlane G.J., Boyle P., Scully C. Oral Cancer in Scotland: Changing Incidence and Mortality. Brit.Med.J. 305:1121-1123, 1992. 166.Scully C., Boyle P.Vitamin A related compounds in the chemoprevention of potentially malignant oral lesions and carcinoma. Eur.J.Cancer. B: Oral Oncology 2:87-89, 1992. 167.Zheng T., Mayne St., Holford T.R., Boyle P., Flannery J. Time Trend and Age-Period-Cohort Effects on Incidence of Esophageal Cancer in Connecticut, 1935-89. Cancer Causes Control 3:481-492, 1992. 168.Zatonski W.A., Boyle P., Przwoniak K., Maisonneuve P., Drosik W., Walker A.M. Cigarette smoking, alcohol, tea and coffee consumption and pancreas cancer risk: a case-control study from Opole, Poland. Int. J. Cancer, 53:601-607, 1993. 169.Zheng T., Boyle P., Willett W.C., Hu H.F., Duan J., Evstifeeva T., Niu S., MacMahon B. A Case-Control Study of Oral Cancer in Beijing, People's Republic of China. Associations with Nutrient Intakes, Foods and Food Groups. Oral Oncology, 29B, 1:45-55, 1993. 170.La Vecchia C., Negri E., Franceschi S., D'Avanzo B., Boyle P. Marital Status, indicators of sexual activity and prostatic cancer. J.Epidemiol.Comm.Health, 47:450-453, 1993. 171.Zaridze D.G., Evstifeeva T., Babaeva M., Boyle, P. Fats used in seasoning and breast cancer risk: a case-control study in Moscow, Russia. Annals Oncology, 4:495-498, 1993. 172.Boyle P. The Hazards of Active and Passive Smoking. Letter to the Editor. N.Engl.J.Med., 329 (21): 1581, 1993. 173.Boyle P., La Vecchia C., Negri E., Lucchini F., Levi F. Trends in diet-related cancers in Japan: a conundrum? (Letter) Lancet, 342: 752, 1993. 174.Boyle P., Macfarlane G.J., Scully C. Oral Cancer: necessity for Prevention Strategies (Editorial). Lancet, 342:1129, 1993. 175.Boyle P., Zaridze D.G. Risk factors for prostate and testicular cancer. Eur.J.Cancer, 7: 1048- 176.Boyle P. The Hazards of Passive and Active Smoking. New Engl.J.Med., 328:1708-1709, C: Users fourneraj Documents PB 2013-06 PB CV.doc 177.Boyle B., Chilvers C., Ferraz E., Hulka B., King R., La Vecchia C., Petitti D., Lumbiganon P., Skegg D., Thomas D., Viegas O., Jordan A., Forthney J., Peterson H., Ramachandran P., Spirtas R.Depot-medroxyprogesterone acetate (DMPA) and cancer: Memorandum from a WHO meeting Bulletin World Health Organization, 71(6):669-676, 1993. 178.Franceschi S., Boyle P., Maisonneuve P., La Vecchia C., Burt A.D., Kerr D.J., Macfarlane G.J., Alexander W.D.The Epidemiology of Thyroid Carcinoma. Critical Reviews in Oncogenesis, 4:25-52, 1993. 179.La Vecchia C., Boyle P. Trends in the tobacco-related cancer epidemic in Europe. Cancer Detection and Prevention, 17(4/5):495-506, 1993. 180.La Vecchia C., Franceschi S., Talamini R., Negri E., Boyle P., D'Avanzo B. Marital Status, Indicators of sexual activity and prostate cancer. J.Epid.Comm.Health, 47:450-453, 1993. 181.La Vecchia C., Levi F., Lucchini F., Negri E., Boyle P. Trends in Cancer Mortality in the USSR, 1965-90. Int.J.Cancer, 56:31-39, 1993. 182.La Vecchia C., Lucchini F., Negri E., Boyle P., Levi F. Trends in Cancer Mortality, 1955-89: Asia, Africa and Oceania. Eur.J.Cancer, 29A-15:2168-2211, 1993. 183.La Vecchia C., Lucchini F., Negri E., Boyle P., Levi F. Trends in cancer mortality in the Americas, 1955-1989. Eur.J.Cancer, 29A:431-470, 1993. 184.Levi F., La Vecchia C., Lucchini F., Boyle P. Cancer Incidence and mortality in Europe, 1983-87.Soz Praventivmed 1993, Suppl. 3, 38: S155-S229, 1993. 185.Lowenfels A.B., Cavallini G., Ammann R.W., Lankisch P.G., Andersen J.R, Dimagno E.P., Andren-Sandberg A., Domellof L., Maisonneuve P., Di Francesco V., Lohr-Happe A., Krag E., Melton L.J., Pitchumoni C.S., Wynn P.S., Boyle P. Pancreatitis and the risk of Pancreatic Cancer. New Eng.J.Med., 328, 20:1433-1437, 1993. 186.Macfarlane G.J., Boyle P., Evstifeeva T., Scully C. Epidemiological Aspects of Lip cancer in Scotland. J.Oral Epi. Comm.Dent., 21:279-82, 1993. 187.Macfarlane G.J., Evstifeeva T., Scully C., Boyle P.The Descriptive Epidemiology of Pharyngeal Cancer in Scotland. European Journal of Epidemiology, 9 (6): 587-590, 1993. 188.Martin-Moreno J.M., Boyle P., Gorgojo L., Maisonneuve P., Fernandez-Rodriguez J.C., Willett W.C., Salvini S. Development and validation of a food frequency questionnaire in Spain. Int.J.Epidemiol., 22, 3:512-519, 1993. 189.Martin-Moreno J.M., Willett W.C., Gorgojo L., Boyle P., Gonzales J., Villar F., Maisonneuve P. Alcoholic beverage consumption and risk of breast cancer in Spain. Cancer Causes and Control, 4:345-353, 1993. C: Users fourneraj Documents PB 2013-06 PB CV.doc 190.Robertson A.G., Robertson C., Boyle P., Symonds R.P., Wheldon T.E. The Effect of Differing Radiotherapeutic Schedules on the Response of Glottic Carcinoma of the Larynx. Eur. J. Cancer, 4 (29A): 501-510, 1993. 191.Schroeder F., Boyle P. Screening for Prostate Cancer: Necessity or Nonsense? Eur. J. Cancer, 5 (29A): 656-661, 1993. 192.Wald N.J., Chamberlain J., Hackshaw A., Anderson T., Boyle P., Forrest P., Frischbier H.J., Hakama M., Rutqvist L.E., Schaffer P., Seradour B., Tabar L., Rosselli Del Turco M., E. Von der Schueren. Report of the European Society of Mastology (EUSOMA). Breast Cancer Screening Evaluation Committee. The Breast, 2:209-216, 1993 193.Zaridze D.G., Evstifeeva T., Boyle P. Chemoprevention of oral Leukoplakia and chronic esophagitis in an area of high incidence of oral and esophageal cancer. Annals Epidemiol., 3:225-234, 1993. 194.Zheng T., Mayne S.T., Holford T.R., Boyle P., Wenliang L., Chen Y., Mador M., Flannery J. The time trend and age-period-cohort effects on incidence of Adenocarcinoma of the stomach in Connecticut, from 1955-1989. Cancer 72, 2:330-340, 1993. 195.Boyle P. Diet in the Aetiology of Cancer (Editorial). Eur.J.Cancer, 30A, No.2, p. 133, 1994. 196.Boyle P. New Insights into the Epidemiology and Natural History of Benign Prostatic Hyperplasia. Prog.Clin.Biol.Res., 386:3-18, 1994. 197.Boyle P. Dietary factors in the Aetiology of Cancer (Editorial). Oncology and Haematology Literature Service, 1 (2):7-8, 1994. 198.Boyle P. Epidemiology of Benign Prostatic Hyperplasia: risk factors and concomitance with Hypertension.Brit.J.Clin.Practice, 74:18-22, 1994. 199.Boyle P., Maisonneuve P., Rotmensz N., Sacchini V., Costa A. Prevention of breast cancer with Tamoxifen Oncology in Practice, 3/94: 9-11, 1994. 200.La Vecchia C., D'Avanzo B., Negri E., Franceschi S., Boyle P. Gastrectomy and subsequent risk of oesophageal cancer in Milan. Journal of Epidemiology and Community Health, 48:310-312, 1994. 201.La Vecchia C., Negri E., Franceschi S., D'Avanzo B., Boyle P. A case-control study of diabetes mellitus and cancer risk. Br.J.Cancer., 70:950-953, 1994. 202.Macfarlane G.J., Plesko I., Kramarova E., Obsitnikova A., Boyle P. Epidemiological features of gastric and oesophageal cancers in Slovakia. British Journal of Cancer, 70:177-179, 203.Macfarlane G.J., Evstifeeva T.V., Robertson C., Boyle P., Scully C. Trends of oral cancer mortality among females worldwide. Cancer Causes and Control, 5: 255-258, 1994. C: Users fourneraj Documents PB 2013-06 PB CV.doc 204.Franceschi S., Levi F., Lucchini F., Negri E., Boyle P., La Vecchia C. Trends in Cancer Mortality in Young Adults in Europe, 1955-1989. Eur.J.Cancer, 30A:2096-2118, 1994. 205.Katsouyanni K., Trichopoulou A., Stuver S., Garas Y., Kritselis A., Kyriakou G., Stoïkidou M., Boyle P., Trichopoulos D. The association of fat and other macronutrients with breast cancer: a case-control study from Greece. Brit.J.Cancer, 70: 537-541, 1994. 206.Macfarlane G.J., Boyle P., Evstifeeva T.V., Robertson C., Scully C. Rising Trends of Oral Cancer Mortality World-wide, The return of an old Public Health Problem. Cancer Causes and Control, 5: 259-265, 1994. 207.Hopper J.L., Giles G.G., McCredie M.R.E., Boyle P. Background, Rationale and Protocol for a Case-Control-Family study of breast cancer. The Breast, 3:79-86, 1994. 208.Macfarlane G.J., Boyle P. The Epidemiology of Oesophageal Cancer in the United Kingdom and other European Countries. J.Roy.Soc.Med., 87:334-337, 1994. 209.Filippini G., Farinotti M., Lovicu G., Maisonneuve P., Boyle P. Mothers' active and passive smoking during pregnancy and risk of brain tumour in children. Int.J.Cancer, 57: 769-774, 1994. 210.Hietanen E., Bartsch H., Bereziat J.C., Camus A.M., McClinton S., Eremin O., Davidson L., Boyle P. Diet and Oxidative Stress in Breast, Colon and Prostate cancer patients: a case- control study. European Journal of Clinical Nutrition, 48: 575-586, 1994. 211.Lowenfels A.B., Maisonneuve P., Cavallini G., Amann R.V., Lankisch P.G., Andersen J.R., Dimagno E.P., Andren-Sandberg A., Domellof L., and the International Pancreatitis Study Group: Listed Authors plus Vincenzo Di Francesco, Paolo Pederzoli, Annette Lohr-Happe, Einar Krag, Peter Boyle, C.S. Pitchumoni, Pe Shein Wynn, and Joseph Melton. Prognosis of Chronic Pancreatitis: an International Multicenter Study Amer.J.Gastroenterology, 9:1467- 212.Martin-Moreno J.M., Boyle P., Gorgojo L., Maisonneuve P., Fernandez-Rodriguez J.C., Willett W.C., Banegas J.R, Artalejo F.R. Dietary fat, olive oil intake and breast cancer risk. Int. J. Cancer, 58:774-780, 1994. 213.McCredie M., Maisonneuve P., Boyle P. Antenatal Risk Factors for Malignant Brain Tumours in New South Wales Children. Int.J.Cancer, 56: 6-10, 1994. 214.McCredie M., Maisonneuve P., Boyle P. Perinatal and early postnatal risks for malignant brain tumours in New South Wales Children. Int. J. Cancer, 56:11-15, 1994. 215.Sagnier P.P., Macfarlane G.J., Richard F., Botto H., Teillac P., Boyle P. Results of an Epidemiological Survey Employing a Modified American Urological Association Symptom Index for Benign Prostatic Hyperplasia in France. J. Urology, 151:1266-1270, 1994. C: Users fourneraj Documents PB 2013-06 PB CV.doc 216.Sagnier P.P., Richard F., Botto H., Teillac P., Dreyfus J.P., Boyle P. Adaptation et validation en langue française du score international des symptomes de l'hypertrophie benigne de la prostate. Prog.Urol., 4: 532-540, 1994. 217.Vela Navarrete R., Martin-Moreno J.M., Calahorra F.J., Damian Moreno J., Herandez Coronado A., Boyle P. Validacion cultural y linguistica, en castellano del baremo internacional de sintomas prostaticos (I-PSS). Actas Urologicas Espanolas, 18: 841-847, 1994. 218.Zheng T., Holford T.R., Boyle P., Chen Y., Ward B.A., Flannery J., Mayne S.T. Time Trend and Age-Period-Cohort Effect of Histologic types of Lung Cancer in Connecticut, 1960-89. Cancer 74, 5:1556-1567, 1994. 219.Zakelj M., Boyle P. Breast Cancer Detection and Oral Contraceptive use in Slovenia (letter). Lancet, 343:1166-1167, 1994. 220.Robertson C., Boyle P., Hsieh C.C., Macfarlane G.J., Maisonneuve P. Some statistical considerations in the analysis of case-control studies when the exposure variables are continuous measurements. Epidemiology, 5(2):164-170, 1994. 221.Macfarlane G.J., Boyle P., Evstifeeva T.V., Robertson C., Scully C. Rising Trends of Oral Cancer Mortality World-wide among women. Cancer Causes and Control, 5:255-258, 1994. 222.Axon A., Boyle P., Riddel R.H., Grandjouan S., Hardcastle J., Yoshida S. Summary of a Working Party on the Surveillance of Premalignant Lesions. Am.J. Gastroenterol., 89:160- 223.Boyle P., Maisonneuve P. Lung Cancer and Tobacco Smoking. Lung Cancer, 12:167-181, 224.Levi F., La Vecchia C., Lucchini F., Boyle P., Negri E. Patterns of childhood cancer mortality: America, Asia and Oceania. Eur.J.Cancer, 31A: 771-782, 1995. 225.Macfarlane G.J., Zheng T., Marshall J.R., Boffetta P., Niu S., Brasure J., Merletti F., Boyle P. Alcohol, Tobacco, Diet and the risk of oral cancer: A pooled analysis of three case-control studies. European Journal of Cancer part B - Oral Oncology, 31B: 181-187, 1995. 226.Macfarlane G.J, Evstifeeva T.V, Boyle P., Grufferman S. International patterns of occurrence of Hodgkin's Disease in children and young adult males. Int. J. Cancer, 61:165-169, 1995. 227.Napalkov P., Maisonneuve P., Boyle P. Worldwide patterns of prevalence and mortality from Benign Prostatic Hyperplasia. Urology, 46 (Supplement 3A): 41-46, 1995. 228.Boyle P., Maisonneuve P., Dore' J.F. Epidemiology of Malignant Melanoma. Brit.Med.Bull., 3:523-547, 1995. 229.Boyle P., Napalkov P. The Epidemiology of Benign Prostatic Hyperplasia and observations on concomitant hypertension. Scand. J.Urol. Nephrol., 29:7-12, 1995. C: Users fourneraj Documents PB 2013-06 PB CV.doc 230.Neglia J., FitzSimmons S., Maisonneuve P., Schoni M., Schoni-Affolter F., Corey M., Lowenfels A., Boyle P., Dozor A., Durie P. The Risk of Cancer Among Patients with Cystic Fibrosis. New Engl. J. Med., 332:494-499, 1995. 231.Boyle P., Chiesa F., Scully C. Chemoprevention and Oral Cancer - (More) trials and (more) tribulations. European Journal of Cancer B. Oral Oncology, 1 (1): 2, 1995. 232.Boyle P. Book Review: R. Doll, J.F. Fraumeni Jr., Muir C.S., Trends in Cancer Incidence and Mortality, Cancer Surveys, Vol. 19/20. Statistics in Medicine, 14: 2507-2508, 1995 (IF 1.085). 233.Boyle P. Progress in Preventing Death from Colorectal Cancer.Editorial. Brit. J.Cancer., 72: 234.Macfarlane G.J., Sagnier P.P., Richard F., Teillac P., Botto H., Boyle P. Determinants of treatment-seeking behaviour for urinary symptoms in older men. Br. J. Urol., 76 (6): 714-718, 1995. 235.Macfarlane G., Evstifeeva T., Boyle P., Grufferman S. International patterns in the occurence of Hodkgin's disease in children and young adult males. Int. J. Cancer, 6: 165- 236.Boyle P., Macfarlane G.J., Blot W.J., Chiesa F., Lefebvre J.L., Mano Azul A., de Vries N., Scul y C. European School of Oncology Advisory Report to the European Commission for the Europe Against Cancer Programme: Oral Carcinogenesis in Europe. Oral Oncology, 31B:75- 237.Sagnier P.P., Macfarlane G.J., Teillac P., Botto H., Richard F., Boyle P. Impact of Symptoms of Prostatism on level of Bother and Quality of Life of men in the French Community. J Urology, 153: 669-673, 1995. 238.Boyle P. Tobacco Smoking: The Worsening of the Epidemic. Editorial for: Literature Reviews. Oncology and Haematology, 3:4-6, 1995. 239.Boyle P. Tobacco and Cancer, the European Perspective. Annals of Oncology, 6: 435-439, 240.Fernandez E., La Vecchia C., Porta M., Negri E., D'Avanzo B., Boyle P. Pancreatitis and the risk of pancreatic cancer. Pancreas, 2 (11):185-189, 1995. 241.Veronesi U., Costa A., Sacchini V., Luini A., Bonanni B., Veronesi P., Rotmensz N., Boyle P. Etude italienne de chimioprevention du cancer du sein avec le tamoxifene. Contracept. Fertil. Sex., 23: 258-260 1995. 242.Boyle P., Maisonneuve P., Napalkov P. Geographical and temporal patterns of incidence and mortality from prostate cancer. Urology 46 (Suppl 3A): 47-55, 1995. C: Users fourneraj Documents PB 2013-06 PB CV.doc 243.Primic Zakelj M., Evstifeeva T., Ravnihar B., Boyle P. Breast cancer risk and oral contraceptive use in Slovenian women aged 25-54. Int J Cancer, 62: 414-420, 1995. 244.Zheng T., Holford T.R., Ward B.A., McKay J., Flannery J., Boyle P. Time Trend in Pancreatic Cancer Incidence in Connecticut, 1935-1990. Int. J. Cancer, 61: 622-627, 1995. 245.Veronesi U., Costa A., Boyle P., Maisonneuve P., Rotmensz N., Zecchini A.M., Barberini M., Bestetti F., Bettega D., Bocciolone L., Bonanni B., Bruno S., Canigiula L., Cassano E., Farante G., Lampreda C., Mascotti G., Ponzone V., Sacchini V., Salvioni A., Travaglini R., Veronesi P., Zocca A., D'Aiuto G., Oliviero P., Rotunno L., Sottana F., Gucciardo G., Marini P., Muraca M.G., Scillone L., Veronesi A., Pizzichetta M., Conforti S., Palazzo S., Audisio R.A., Ravaioli R., Rulli A., Pluchinotta A., Modena S., Molino A.M., Zannoni E., Valentini M., Depalma P., Baratelli G., Barros A., Bernardo G., Bocchiotti G., Bonsignori M., Bottinelli G., Carnaghi P., Colombo P., Cresta C., D'Amore L., Della Torre L., Donadello N., Dossena G., Ferrari A., Frasson A., Guidetti R., Leonardi F., Luerti M., Magro A.G., Pagni P., Raia F., Rocci R., Schittuli F., Tommasini A., Zanella B., Albisetti W., Coopmans De Yoldi G., Decensi A., Di Maggio C., Guazzi M., Luini A., Maltoni C., Mannucci P.M., Pardi G., Podda M., Ravasi G., Scaltrini G., Turbati M. Prevention of breast cancer with Tamoxifen: The Italian study in Hysterectomized women. The Breast, 4: 267-272, 1995. 246.Robertson C., Boyle P., Hsieh C.C., Macfarlane G., Maisonneuve P. Interpretation and Analyses of differential exposure variability and zero-exposure categories for continuous exposures. Epidemiology 6(3):335, 1995. 247.Boyle P., Primic-Zakelj M. Review article. European Code Against Cancer. Journal of Slovene Medical Society, 64:447-452, 1995. 248.Boyle P., Veronesi U., Tubiana M., Alexander F.E., Calais da Silva F., Denis L.J., Freire J.M., Hakama M., Hirsch A., Kroes R., La Vecchia C., Maisonneuve P., Martin-Moreno J.M., Newton-Bishop J., Pinborg J.J., Saracci R., Scully C., Standaert B., Storm H., Blanco S., Malbois R., Bleehen N., Dicato M., Plesnicar S. Special Paper. European School of Oncology Advisory Report to the European Commission for the "Europe Against Cancer Programme"European Code Against Cancer. Eur. J. Cancer, 9: 1395-1405, 1995. 249.Boyle P. The Revised European Code Against Cancer. Oncology in Practice, 3: 4-8, 1995. 250.Boyle P., Primic Zakelj M. Eropski Kodeds Proti Raku. Zdravstveno Varstvo, 34: 411-2, 251.Boyle P., Primic Zakelj M. European Code against Cancer. Radiol. Oncol., 29: 248-9, 1995. 252.Boyle P., Maisonneuve P and Steg A. Decrease in mortality from benign prostatic hyperplasia: a major unheralded health triumph. Journal Urology, 155:176-180, 1996. 253.Zheng T., Holford T.R., Chen Y., Ma J.Z., Flannery J., Liu W., Russi M., Boyle P. The Time Trend and Age-period Cohort Effect on Incidence of Thyroid Cancer in Connecticut, 1935-1992. Int. J. Cancer, 67: 504-509, 1996. C: Users fourneraj Documents PB 2013-06 PB CV.doc 254.Boyle P., Maisonneuve P., Napalkov P. The incidence of Prostate Cancer will double by the Year 2030: The Argument For. Eur. Urol., 29:3-9, 1996. 255.Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormonal contraceptives: Further Results. Contraception, 54 (Suppl. 3):1S-106S, 1996. 256.Marshall J., Boyle P. Nutrition and Oral Cancer. Cancer Cause Control , 7 (1): 101-111, 257.Plesko I., Ondrus D., Boyle P. Testicular cancer incidence and mortality in Slovakia, 1968- 1990. Lancet, 347: 900-901, 1996. 258.Macfarlane G.J., Botto H. Sagnier P.P., Teillac P., Richard F., Boyle P. The relationship between sexual life and urinary condition in the French community. J. Clin. Epidemiol., 49(10): 1171-1176, 1996. 259.Salvini S., Gnagnarella P., Parpinel M.T., Boyle P., Decarli A., Ferraroni M., Giacosa A., La Vecchia C., Negri E., Franceschi S. The Food Composition Database for an Italian Food Frequency Questionnaire. Journal of Food Composition and Analysis, 9:57-71, 1996. 260.Buccianti G., Maisonneuve P., Ravasi B., Cresseri D., Locatelli F., Boyle P. Cancer among patients on renal replacement therapy. A population-based survey in Lombardia, Italy. Int. J. Cancer, 66:591-593, 1996. 261.Sagnier P., Girman C., Garraway M., Jumamoto T., Lieber M., Richard F., Macfarlane G., Guess H., Jacobsen S., Tsukamoto T., Boyle P. International Comparison of the Community Prevalence of Symptoms of Prostatism in Four Countries. Eur. Urol., 29: 15-20, 1996. 262.Boyle P., Napalkov P. Epidemiology of Benign Prostatic Hyperplasia: Current Perspectives. European Urology 29 (1): 7-11, 1996. 263.Cattaruzza M.S., Maisonneuve P., Boyle P. Occasional Review: Epidemiology of Laryngeal Cancer. Oral Oncol., Eur.J.Cancer, 32B:293-305, 1996. 264.Boyle P., Gould L., Roehrborn C. Prostate Volume Predicts Outcome of Treatment of Benign Prostatic Hyperplasia with Finasteride. Meta-Analysis of Randomized Clinical Trials.Urology, 48(3): 398-405, 1996. 265.Negri E., La Vecchia C., Levi F., Franceschi S., Serra-Majem L., Boyle P. Comparative Descriptive Epidemiology of Oral and Esophageal Cancers in Europe. Eur. J. Cancer Prev., 5: 266.Zheng T., Holford T.R., Zheng M.A., Ward B., Falnnery J., Boyle P. Continuing increase in incidence of germ-cell testis cancer in young adults: experience from Connecticut, USA, 1935-1992. Int. J.Cancer 65, 723-729, 1996. C: Users fourneraj Documents PB 2013-06 PB CV.doc 267.Schöni H.M., Maisonneuve P., Schöni-Affolter F., Lowenfels A.B., Boyle P., Members of the
CF/CSG Group.Cancer risk in patients with cystic fibrosis: the European data. J. Roy. Soc. Med., 89 (27): 38-43 1996. 268.Zheng T., Holford T.R., Ma Z., Chen Y., Liu W., Ward B.A., Boyle P. The Continuing Increase in Adenocarcinoma of the Uterine Cervix: A Birth Cohort Phenomenon. Int. J. Epi., 25 (2): 252-258, 1996. 269.Boyle, P. Continual importance of descriptive epidemiology in cancer research (Editorial). Ann. Oncol., 7: 439-440, 1996. 270.Boyle P. Prostate Cancer: Creation and Control of an Epidemic. J. Epi. Bio., (1) 2: 65-67, 271.Boyle P., Kornacker M., Diehl V. Europäischer Kodex gegen den Krebs. Empfehlungen Medizinische Klinik, 91: 262-267, 1996. 272.Boyle P., Kubik A. Revidované Zneni Europského Kodexu Proti Zhoubným Nàdorum. Cas. Lek. ces., 22: 711-715, 1996. 273.Zheng T., Holford R., Chen Y., Ma J.Z., Mayne S.T., Boyle P., Flannery J. Time Trend and Age-Period Cohort Effect on Incidence of Bladder Cancer in Connecticut,1935-1992. Int. J. Cancer, 68: 172-176, 1996. 274.Buccianti G., Ravasi B., Cresseri D., Maisonneuve P., Boyle P., Locatelli F. Cancer in patients on renal replacement therapy in Lombardy, Italy. (Letter). The Lancet, 347 (8993): 59-60, 1996. 275.Boyle P., La Vecchia C. Introducing the Journal of Epidemiology and Biostatistics.Editorial. J. Epi. Bio., 1: 1-2, 1996. 276.Boyle P. The Epidemiology of Malignant Melanoma Rev. Argent. Canc. XXIV (1): 26-32, 277.Boyle P., Plesko I. Európsky kódex proti rakovine. Slovensky Lekár, 4: 30-35, 1996. 278.Boyle P. Exogenous Hormones and Cancer Risk in Women. What should women be advised to do? Eur. Cancer News, 8:4-7, 1996. 279.Boyle P., Eckhardt S. Európai Rákellenes Kódex. Magyar Onkológia, 2:68-75, 1996. 280.Alexander F.E., Wray N., Boyle P., Bring J., Coebergh J.W., Draper G., Levi F., McKinney P.A., Michaelis J., Peris-Bonet R., Petridou E., Pukkala E. Storm H., Terracini B., Vatten L. Review: Clustering of childhood leukemia leukaemia: a European study in progress. J.Epi.Bio., 1: 13-22, 1996. 281.Boyle P. L'epidemiologia del cancro in Europa. Le Scienze, 339:88-89, 1996. C: Users fourneraj Documents PB 2013-06 PB CV.doc 282.Boyle P. European Cancer Experts Recommendations for Tobacco Control. Eur.Canc.News., 9(9) 8-11, 1996. 283.Rocco F., De Cobelli O., Maffezzini M., Franchini V., Scardino E., Carmignani L., Andres M., Frea B., Crispino S., Tancini G., Paolorossi F., Boyle P., Maisonneuve P. Neoadjuvant chemotherapy and conservative surgery for locally advanced transitional cell bladder cancer. J. Chemotherapy, 8 (4): 326-327, 1996. 284.Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53.297 women with breast cancer and 100.239 women without breast cancer from 54 epidemioological studies. Lancet, 347: 1713-1727, 1996. 285.Boyle P. European cancer experts' recommendations for tobacco control. J. Epi. Bio., 1(3):121-123, 1996. 286.Zatonski W.A., Boyle P. Health transformations in Poland after 1988. J. Epi. Bio., 1(4): 183- 287.Andreoni B., Crosta C., Biffi R., Marzona L., Pozzi S., Lotti M. e C.T.S.U.O. Regione Lombardia. Attivazione nella Regione Lombardia del Trial multicentrico "Once only sigmoidoscopy"per lo screening del carcinoma colorettale. Minerva Chir.(Suppl. 1 al N.6), 51: 43-50, 1996. 288.Boyle P., Primic Zakelj M. Eropski Kodeds Proti Raku. European Code Against Cancer. Obzornik Zdravstvene nege, 30: 3-5, 1996. 289.Boyle P, Maisonneuve P, Bueno de Mesquita B, Ghadirian P, Howe GR, Zatonski W, Baghurst P, Moerman CJ, Simard A, Miller AB, Przewoniak K, McMichael AJ, Hsieh CC, Walker AM. Cigarette smoking and pancreas cancer: a case control study of the search programme of the IARC. Int J Cancer 1996 Jul 3;67(1):63-71 290.Zatonski W., Lowenfels A.B., Boyle P., Maisonneuve P., Bueno de Mesquita B., Ghadirian P., Jain M., Preznowiak K., Baghurst P., Moerman C.D., Simard A., Howe G.R., McMichael A.J., Hsieh C.C., Walker A.M. Epidemiological aspects of gallbladder cancer: a case-control study of the SEARCH Programme of the IARC. J.N.C.I., 89 (15): 1132-1138, 1997. 291.Boyle P., Krewski D., Ashmore J.P., Cardis E., Zielinski J.M. Radiation Epidemiology and National Dose Registers. Proceedings of the Workshop held at University of Toronto, 13-14 July 1992. Eur. J.Cancer, 33: (Suppl. 3):S1-S2, 1997. 292.Ghadirian P., Lacroix A., Maisonneuve P., Perret C., Potvin C., Gravel D., Bernard D., Boyle P. Nutritional Factors and Colon Carcinoma. A case-control study involving French Canadians in Montreal, Quebec, Canada. Cancer, 80:858-864, 1997. 293.Fernandez E., La Vecchia C., Porta M., Negri E., D'Avanzo B., Boyle P. Pancreatitis and the risk of Pancreatic Cancer: In Response to Gullo & Pezzilli. Pancreas, 14:106-107, 1997. C: Users fourneraj Documents PB 2013-06 PB CV.doc 294.Lowenfels A.B., Maisonneuve P., DiMagno E., Elitsur Y., Gates L.K., Perrault J., Whitcomb D.C. and the International Hereditary Pancreatitis Study Group. Hereditary Pancreatitis and the Risk of Pancreatic Cancer. J. Natl. Cancer I., 89 (6): 442-446, 1997. 295.Zheng T., Holford T.R., Chen Y., Ward B., Liu W., Flannery J., Boyle P. Are Cancers of the Salivary Gland Increasing? Experience from Connecticut, USA. Int. J. Epidemiol., 26: 264- 296.Zheng T., Holford T.R., Chen Y., Ward B., Liu W., Flannery J., Boyle P. Are Cancers of the Salivary Gland Increasing? Experience from Connecticut, USA. Int. J. Epidemiol., 26: 264- 297.Zheng T., Holford T.R., Chen Y., Ma Z., Liu W.L., Flannery J., Boyle P. Lymphocytic Leukemias in Connecticut, USA: Time Trends and Racial Differences, 1935-1992. J. Epi. Bio., 1(4): 219-225, 1997. 298.Chen Y., Zheng T., Chou M., Boyle P., Holford T.R. The increase of Hodgkin's disease incidence among young adults: experience in Connecticut 1935-1992. Cancer, 79 (11): 2209-2218, 1997. 299.Zheng T., Holford T., Chen Y., Jiang P., Zhang B., Boyle P. Risk of Tongue Cancer Associated with Tobacco Smoking and Alcohol Consumption: A Case-Control Study. Oral Oncol., 33 (2): 82-85, 1997. 300.Boyle P. European Cancer Experts Recommendations for Tobacco Control. Annal. Oncol., 301.Boyle P. Cancer, Cigarette smoking and premature death in Europe. A review including the Recommendations of European Cancer Experts Consensus Meeting, Helsinki, October 1996. Lung Cancer, 17: 1-60, 1997. 302.Boyle P., Krewski D., Ashmore J.P., Cardis E., Zielinski J.M. Radiation Epidemiology and National Dose Registers. Eur. J.Cancer, 33: Suppl. 3,S1-S2, 1997. 303.Andersen J.T., Nickel J.C., Marshall V.R., Schulman C.C. and Boyle P. Finasteride significantly reduces acute urinary retention and the need of surgery in patients with symptomatic Benign Prostatic Hyperplasia. Urology, 49:839-845, 1997. 304.Boyle P. Global burden of cancer. Lancet, 349 (Oncology Supplement II): 23-26, 1997. 305.Autier P., Dore' J.F., Cesarini J.P., Boyle P. and the epidemiology & Prevention subgroup, the EORTC Melanoma Cooperative Group and the EORTC Prevention Research Division. Should subjects who used psoralen suntan activators be screened for Melanoma? Ann. Oncol., 8(5):435-437, 1997. 306.Osborne M., Boyle P., Lipkin M. Cancer Prevention. Lancet, 349 (Oncology supplement II): C: Users fourneraj Documents PB 2013-06 PB CV.doc 307.Boyle P. Cultural and linguistic validation of questionnaires for use in international studies: the nine-item BPH-specific quality of life scale. Eur. Urol., 32 (suppl 2): 50-52, 1997. 308.Becker N., Boyle P. Decline in mortality from testicular Cancer in West Germany after re- unification. (Research Letter) Lancet, 350: 744, 1997. 309.Boyle P., La Vecchia C. Journal of Epidemiology and Biostatistics: the first year. J. Epi. Bio., 310.Boyle P. Editorial: Some current issues in population screening for cancer. J. Epi. Bio., 2 311.Gray N., Boyle P. Attacks on tobacco Industry (The US Settlement) (Letter). The Lancet, 312.Tradati N., Grigolato R., Calabrese L., Costa L., Giugliano G., Morelli F., Scully C., Boyle P., Chiesa F. Oral Leukoplakias: to treat or not to treat? Oral Oncology, 33 (5): 317-321, 1997. 313.Collaborative group on hormonal factors in breast cancer. Breast Cancer and Hormone Replacement Therapy. Lancet, 350: 1047-1059, 1997 314.Zakelj M., Robertson C., Boyle P., Hsieh C., Effect of Parity and age at delivery on breast cancer risk in slovenian Women aged 25-54, Int. J Cancer, 73:1-9, 1997 (3.403) 315.Boyle P. Editorial: Epidemiology of scientific misconduct. J. Epi. Bio., 2(2): 61-63, 1997. 316.Boyle P., Maisonneuve P., Napalkov P. Commentary: Urological cancers: epidemiological overview of a neglected problem. J. Epi. Bio., 2 (3):125-145, 1997. 317.Boyle P. Editorial. Gynaecological cancer survival: monitoring international and temporal variation. J Epi Bio, 2 (4): 185-186, 1997. 318.Boyle P. Cancer, Cigarette Smoking and premature death in Europe. In: European Strategy to promote Health and non-smoking. Europe Against Cancer. High level Cancer Experts Committee. Consensus Conference on Tobacco, Helsinki, October 2nd, 1996. Oy Edita AB, 319.Robertson C. and Boyle P. Statistical Modelling of Breast Cancer Incidence and Mortality Rates in Scotland. Brit J Cancer, 76 (9): 1248-1252, 1997 320.Franklyn J.A., Maisonneuve P., Sheppard M.C., Betteridge J., Boyle P. Mortality after the Treatment of Hyperthyroidism with Radioactive Iodine. New Engl J Med, 338: 712-8, 1998. 321.LaVecchia C, Negri E, Levi F, Lucchini, Boyle P.Cancer Mortality in Europe: Effects of age, Cohort of Birth and Period of Death. Eur J Cancer, 34 (1): 118-141, 1998. 322.Alexander F., Boyle P., Carli P.M., Coebergh J.W., Draper G., Ekbom A., Levi F., McKinney P.A., McWhirter W., Magnani C., Michaelis J., Olsen J.H., Peris-Bonet R., Petridou E., Pukkala C: Users fourneraj Documents PB 2013-06 PB CV.doc E., Terracini B., Vatten L. on behalf of the EUROCLUS project. Spatial Temporal Patterns in Childhood Leukaemia: further evidence for an infectious origin. Brit J Cancer, 77:812-817, 1998 (IF 3.666) 323.Decensi A., Bonanni B., Guerrieri-Gonzaga A., Gandini S., Robertson C., Johansson H., Travaglini R., Sandri M.T., Tessadrelli A., Farante G., Salinaro F., Bettega D., Barreca A., Boyle P., Costa A., Veronesi U. Biologic activity of Tamoxifen at low doses in healthy women. JNCI, 90 (19): 1461-1468, 1998 324.Alexander F., Boyle P., Carli P.M., Coebergh J.W., Draper G., Ekbom A., Levi F., McKinney P.A., McWhirter W., Michaelis J., Peris-Bonet R., Petridou E., Pompe-Kirn V., Plesko I., Pukkala E., Rahu M., Storm H., Terracini B., Vatten L., Wray N. on behalf pf the EUROCLUS project. Spatial Clustering of Childhood Leukaemia: Summary Results from the EUROCLUS project. Brit J Cancer , 77:818-824, 1998 (IF 3.666) 325.Robertson C. and Boyle P. Statistical Modelling of Breast Cancer Incidence and Mortality Rates in Scotland. Brit J Cancer, 76 (9): 1248-1252, 1997 326.LaVecchia C, Negri E, Levi F, Lucchini, Boyle P. Cancer Mortality in Europe: Effects of age, Cohort of Birth and Period of Death., Eur J Cancer, 34 (1); 118-141, 1998. 327.Mezzetti M., La Vecchia C., Decarli A., Boyle P., Talamini R., Franceschi S. Population risk for breast cancer : diet, nutrition and physical exercise. J Natl Cancer Inst, 90: 389-94, 1998. 328.Calabrese L., Tradati N., Nickolas T.L., Giugliano G., Zurrida S., Scully C., Boyle P., Chiesa F. Review. Cancer screening in otorhinolaryngology. European J Cancer, 34: 1-4, 1998 329.Robertson C., Boyle P. Modeling Temporal Aspects of an Exposure (Letter). Epidemiology, 9 (3): 361-362, 1998. 330.Dore J-F., Maisonneuve P., Cattaruzza M.S., Autier P., Cochran A.J., Boyle P. A molecular epidemiological approach to the study of expression of a metastasis marker in primary melanomas and its correlation with individual patients's risk of recurrence or metastasis. Melanoma Research, Suppl. 7(2): 121-125, 1997. 331.Ghadirian P, Lacroix A, Perret C, Robidoux A, Falardeau M, Maisonneuve P, Boyle P. Breast Cancer Risk and Nutrient Intake Among French Canadians in Montreal: a Case Control Study.The Breast, 7: 108-113, 1998 332.Boyle P. Osservazioni relative all'epidemiologia della ritenzione urinaria acuta. (Some Remarks on the Epidemiology of Acute Urinary Retention). Archivio Italiano Urologia Andrologia, spec.-suppl al n. 2, 1998. 333.Robertson C., Boyle P. Age-Period-Cohort of Chronic Disease Rates - I Modelling Approach. Statist. Med., 17: 1305-1323, 1998. C: Users fourneraj Documents PB 2013-06 PB CV.doc 334.Bartsch H, Malaveille C., Lowenfels A.B., Maisonneuve P., Hautefeuille A., Boyle P. and the International Pancreatic Disease Study Group. Genetic polymorphism of N-acetyltransferases, glutathione S-transferase M1 and NAD(P)H: quinone oxidoreductase in relation to malignant and benign pancreatic disease risk. Eur J of Cancer Prevention, 7: 215-223, 1998. 335.Veronesi U., Maisonneuve P., Costa A., Sacchini V., Maltoni C., Robertson C., Rotmensz N., Boyle P. on behalf of the Italian Tamoxifen Study Group. Prevention of Breast cancer with The Italian Randomised Trial among Hysterectomised women. The Lancet, 352: 93-97, 1998. 336.Boyle P., Autier P. Editorial: Colorectal Cancer Screening. Health policy or a continuing Research Issue? Annals of Oncology, 9:581-584, 1998. 337.Robertson C. and Boyle P. Age-Period-Cohort of Chronic Disease Rates - II Graphical Approaches. Statist. Med., 17:1325-1340, 1998. 338.Robertson C., Boyle P. Age at any birth and Breast Cancer Risk. Stat.Med., 17: 431-445, 1998. (IF 1.250) 339.Decensi A., Robertson C., Rotmensz N., Severi G., Maisonneuve P., Sacchini V., Boyle P., Costa A., Veronesi U. on behalf of the Italian Chemoprevention Group. Effect of Tamoxifen and Transdermal hormone replacemente therapy on cardiovascular risk factors in a prevention trial. Brit. J. Cancer, 78(50): 572-578, 1998. 340.Gray N., Boyle P., Zatonski W. Tar concentrations in cigarettes and carcinogen content. Lancet, 352:787-788, 1998. 341.Levi F., Lucchini F., Boyle P., Negri E., La Vecchia C. Cancer Incidence and mortality in Europe, 1988-92. J. Epi. Bio, 3(3), Suppl, 1998. 342.Autier P., Boyle P., J.F.Dore'. Letter: Sorting the hype from the facts in melanoma. Lancet, 343.Boyle P., Horton R., Radda G., Sharp D., Veronesi U., Walker A.M. Open debate on HRT. Lancet, 352:836, 1998. 344.Ghadirian P., Maisonneuve P., Perret C., Lacroix A., Boyle P. Epidemiology of sociodemographic characteristics, lifestyle, medical history and colon cancer: A case-control study among French Canadians in Montreal. Cancer Detect. Prev. 22 (5): 396-404, 1998 345.Boyle P., Keech M., Nonis A., Fourcade R., Hobbs R., Kiemeney L.A.M., Lee Chungwook., Maier W., Watson M., Robertson C. The UrEpik Study: A cross-sectional survey of benign prostatic hyperplasia, urinary incontinence and male erectile dysfunction, prostatitis and interstitial cystitis in the United Kingdom, France, the Netherlands and Korea. J Epi Bio, 3 (2):179-187, 1998. C: Users fourneraj Documents PB 2013-06 PB CV.doc 346.Ghadirian P., Lacroix A., Perret C., Maisonneuve P., Boyle P. Sociodemographic characteristics, smoking, medical and family history and breast cancer. Cancer Detection and Prevention, 22 (6): 485-494, 1998 347.Boyle P. Prostate Specific Antigen (PSA) testing as screening for prostate cancer. The Current Controversy. Ann. Oncol., 9:1263-1264, 1998. (IF 2,736) 348.Boyle P. Expanding on epidemiology's first principles. Book review: Modern Epidemiology by K. Rothman et al. Lancet, 352:1635-1636, 1998 349.Langman MJS, Boyle P. Chemoprevention of Colorectal Cancer. Gut, 43(4): 578-585, 1998 350.Girman C.J., Jacobsen S.J., Tsukamoto T., Richard F.,Garraway M., Sagnier P.P, Guess H.A., Rhodes T., Boyle P., Lieber M.M. Health-Related quality of life associated with lower urinary tract symptoms in four countries. Urology, 51:428-436, 1998 351.Denis L., Pagano F., Nonis A., Robertson C., Romano P., Boyle P. A double-blind placebo- controlled trial to assess the efficacy and tolerability of Mepartricin in the treatment of BPH. Prostate, 37:246-252, 1998 IF 2.552 352.Veronesi U., Maisonneuve P., Costa A., Rotmensz N., Boyle P. Drop-outs in Tamoxifen Prevention Trials. Lancet, 353:244,1999 353.Boyle P, Maisonneuve P, Autier P. Towards cancer control in women. J Epi Bio, 3(1):137- 354.Boyle P. Epidemiology of Lung Cancer: a century of great success and ignominious failure. Respiratory Care Matters, 3 (4): 8-9, 1999. 355.Roehrborn C.G., Boyle P., Gould L., Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with BPH. Urology, 53(3)581-589, 1999. 356.Boyle P., La Vecchia C. Editorial: Preparing for the Millennium. J Epi Bio, 4 (1): 1-2, 1999. 357.Boyle P, Severi G. Epidemiology of Prostate Cancer Chemoprevention. Eur Urol, 35: 370- 358.Kirby R., Robertson C., Griffiths K., Denis L.J., Boyle P. Finasteride in association with either Flutamide or Goserelin as Combination Hormonal Therapy in Patients with stage M1 Carcinoma of the prostate. Prostate 1999; 40: 105-114 359.Alexander F.E., Boyle P., Carli M., Coebergh J.W., Ekbom A., Levi F., McKinney P.A., McWhirter W., Michaelis J., Peris-Bonet R., Petridou E., Pompe-Kirn V., Plesko I., Pukkala E., Rahu M., Stiller C.A., Storm H., Terracini B., Vatten L., Wray N., on behalf of the EUROCLUS project. Population density and childhood leukaemia: results of the EUROCLUS study. Eur J Cancer, 1999; 35 (3): 439-444. C: Users fourneraj Documents PB 2013-06 PB CV.doc 360.Zheng T., Holford T.R., Mayne S.T., Owens P.H., Ward B., Carter D., Dubrow R., Zahm S.H., Tessari J D.and Boyle P. Environmental exposure to hexachlorobenzene (HCB) and risk of female breast cancer in Connecticut, USA. Cancer Epidemiology and Biomarkers 1999; 8: 361.Franklyn J.A., Maisonneuve P., Sheppard M., Betteridge J., Boyle P. Cancer Incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. The Lancet, 353: 2111-2115, 1999 362.Maisonneuve P., Agodoa L., Gellert R., Stewart J.H., Buccianti G., Lowenfels A.B., Wolfe R.A., Jones E., Disney A., Briggs D., McCredie M., Boyle P. Cancer in end stage renal disease patients undergoing dialysis: results from an international collaborative study. Lancet, 1999; 354: 93-96. 363.Clinical Synthesis Panel on HRT. Clinical Synthesis Conference on Hormonal; Replacement Therapy. Lancet 1999; 354: 152-156 364.Maisonneuve P., Agodoa L., Gellert R., Stewart J.H., Buccianti G., Lowenfels A.B., Wolfe R.A., Jones E., Disney A.P., Briggs D., McCredie M., Boyle P. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet, 354: 93-99, 1999
365.Zheng T., Holford T.R., Mayne S.T., Owens P.H., Ward B., Carter D., Dubrow R., Zahm
S.H., Boyle P Tessari J.,. B-Benzene Hexachloride in Breast cancer adipose tissue and risk of breast carcinoma. Cancer Cancer, 85(10): 2212-2216, 1999. 366.Lowenfels A.B., Maisonneuve P., Boyle P., Zatonski W.A. Epidemiology of gallbladder cancer. Hepato-gastroenterology, 46:1529-1532, 1999 367.Clinical Synthesis Panel on HRT. Clinical Synthesis Conference: Hormone replacement therapy. Lancet, 354: 152-155, 1999 368.Robertson C., Gandini S.and Boyle P. Age-Period-Cohort Models: A Comparative Study of Available Methodologies. Journal of Clinical Epidemiology, 52 (6): 569-583, 1999 369.Levi F., Lucchini F., Negri E., Boyle P. and La Vecchia C. Cancer Mortality in Europe, 1990- 1994, and an Overview of Trends from 1955 to 1994. The European Journal of Cancer, 35 (10) 1477-1516, 1999. 370.Gray N., Zatonski W., Boyle P. Regulation of carcinogens in cigarettes. The Lancet, 18 (354): 1036, 1999 371.Roehrborn C.G., Boyle P., Bergner D., Gray T., Gittelman M., Shown T., Melman A., Bracken RB., de Vere White R., Wang D., Waldstreicher J. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomised trial comparing Finasteride versus placebo (PLESS Study Group). Urology 54: 662-669, 1999. C: Users fourneraj Documents PB 2013-06 PB CV.doc 372.Zheng T., Holford TR., Mayne ST., Ward B., Carter D., Owens PH., Dubrow R., Zahn SH., Boyle P., Archibeque S., Tessari J. DDE and DDT in breast adipose tissue and risk of female breast cancer. Am J Epidemiol, 150(5): 453-8, 1999 373.Levi F., Lucchini F., Negri E., Boyle P. and La Vecchia C. Cancer Mortality in Europe, 1990- 1994, and an Overview of Trends from 1955 to 1994. The European Journal of Cancer, 35: (10) 1477-1516, 1999. 374.Franceschi S., Levi F., Conti E., Talamini R., Negri E., Dal Maso L., Boyle P., Decarli A., La Vecchia C. Energy Intake and Dietary Pattern in Cancer of the Oral Cavity and Pharynx. Cancer Causes and Control, 10: 439-444, 1999. 375.Boyle P, Horton R, Walker AM, Sharp D and Delmas P. Clinical Synthesis Meeting on Osteoporosis. Lancet 1999; Nov 13;354(9191):1664. 376.Severi G, Plesko I, Robertson C, Obsitnikova A and Boyle P. Larynx cancer in Slovakia and the role of anatomical sites. Oral Oncology 1999; 35: 564-570 377.Clinical Synthesis Panel on HRT. Editorial: Hormone Replacement Therapy. Journal of Epidemiology and Biostatistics, 4 (3): 123-128, 1999. 378.Maisonneuve P., Agodoa L., Gellert R., Stewart J.H., Buccianti G., Lowenfels A.B., Wolfe R.A., Jones E., Disney A.P., Briggs D., McCredie M., Boyle P. Distribution of primary renal diseases leading to end stage renal failure in the United States, Europe, and Australia and New Zealand: results from an International comparative study. Am. J. of Kidney Diseases, 2000: 35(1): 157-165. 379.Gandini S., Merzenich H., Robertson C., Boyle P. Review on diet and breast cancer risk: the role of vegetables and fruits consumption and related vitamins. European Journal of Cancer 2000; 36(5): 636-646. 380.Boyle P., Robertson C., Lowe F., Roehrborn C. Meta-analysis of clinical trials of Permixon in the treatement of BPH. Urology, 2000; 55(4): 533-539. 381.Zheng T, Holford TR, Mayne ST, Tessari J, Ward B, Carter D, Owens PH, Boyle P, Dubrow R, Archibeque-Engle S, Dawood O, Zahm SH. Risk of female breast cancer associated with serum polychlorinated biphenyls and 1,1-dichloro-2,2'-bis(p-chlorophenyl)ethylene. Cancer Epidemiol Biomarkers Prev. 2000 Feb;9(2):167-74. 382.Zheng T, Holford TR, Mayne ST, Owens PH, Zhang B, Boyle P, Carter D, Ward, B, Zhang Y, Zahm SH. Exposure to electromagnetic fields from use of electric blankets and other in-home electrical appliances and breast cancer risk. Amer J Epidemiol 2000 Jun 1;151(11):1103-11. 383.Severi G, Giles GG, Robertson C, Boyle P, Autier P. Mortality from cutaneous melanoma: evidence for contrasting trends. Br J Cancer 2000 Jun;82(11):1887-91 384.Boyle P, Langman JS. Epidemiology. BMJ. 2000 Sep 30;3 21(7264):805-808. C: Users fourneraj Documents PB 2013-06 PB CV.doc 385.Autier P, Severi G, Boyle P, Dore JF. More About: Sunscreen Use and Duration of Sun Exposure: a Double-Blind, Randomized Trial. J Natl Cancer Inst. 2000 Sep 20;92(18):1532- 386.Boyle P, Maisonneuve P, Autier P. Update on cancer control in women. Int J Gynaecol Obstet. 2000 Aug;70(2):263-303. 387.Zheng T, Holford TR, Tessari J, Mayne ST, Owens PH, Ward B, Carter D, Boyle P, Dubrow R, Archibeque-Engle S, Zahm SH. Breast cancer risk associated with congeners of polychlorinated biphenyls. Am J Epidemiol. 2000 Jul 1;152(1):50-8. 388.Gray NJ, Zaridze DG, Robertson C, Krivosheeva L, Sigacheva N, Boyle P, and the International Cigarette Variation Group. Variation within global cigarette brands in tar, nicotine, and certain nitrosamines: analytic study. Tobacco Control 2000; 9: 351-352 389.Boyle P., Gandini S., Robertson C., Zatonski W., Fagerstrom K., Slama K., Kunze M. Gray N. and the International Smokers Survey Group. Characteristics of Smokers'Attitudes Towards Stopping: Survey of 10,295 Smokers in Representative Samples from 17 European Countries. Eur J Publ Health 10: 5-14, 2000 390.Plesko I., Severi G., Obsitnikova A., Boyle P. Trends in the incidence of non-melanoma skin cancer in Slovakia, 1978-1995. Neoplasma, 47:132-147, 2000 391.Sonke G.S., Kolman D., de la Rosette J.J., Donkers L., Boyle P., Kiemeney L.A.L.M. Prevalentie van lagere urinewegsymptomen bij mannen en de invloed op hun kwaliteit van leven: de Boxmeer studie" (Prevalence of LUTS among men and influence on their QoL: the Boxmeer study. The Netherlands Tijdschrift voor Geneesunke. Ned Tijdschr Geneeskd 2000 Dec 30;144(53):2558-63 392.Ghadirian P., Maisonneuve P., Perret C., Kennedy G., Boyle P., Krewski D., Lacroix A. A case-control study of toenail selenium and cancer of the breast, colon and prostate. Cancer Detection and Prevention 24:305-313, 2000. 393.Zheng T, Holford, Tr Tessari, J. Mayne St., Zahm Sh., Owens Ph., Zhang B., Ward B., Carter D., Zhang Y., Zhang W., Dubrow R. Boyle P. Oxychlordane and trans-nonachlor in breast adipose tissue and risk of female breast cancer. J. Epi. Bio, 5: 153-160, 2000. 394.Gray N., Boyle P. The Regulation of Tobacco and Tobacco Smoke. Ann. Oncol., 11:909- 395.Boyle P, Bellanti JA and Robertson C. Meta-analysis of published clinical trials of Ribosomal vaccine (Ribomunyl) in prevention of respiratory infections. BioDrugs 2000; 145 (6): 389- 396.Holford TR, Zheng T, Mayne ST, Zahm SH, Tessari JD, Boyle P. Joint effects of nine polychlorinated biphenyl (PCB) congeners on breast cancer risk. Int J Epidemiol 2000 Dec;29(6):975-82 C: Users fourneraj Documents PB 2013-06 PB CV.doc 397.Robertson C, Perone C, Primic-Zakelj M, Kirn VP, Boyle P. Breast cancer incidence rates in Slovenia 1971-1993. Int J Epidemiol 2000 Dec;29(6):969-74 398.Levi F, La Vecchia C, Boyle P. The rise and fall of prostate cancer. Eur J Cancer Prev 2000 399.Gray N., Boyle P. Tobacco Industry must not dump its high nitrosamine tobacco on poor countries. BMJ, 2001; 322:557. 400.Kubik A, Zatloukal P, Boyle P, Robertson C, Gandini S, Tomasek L, Gray N, Havel L. A case- control study of lung cancer among Czech women. Lung Cancer 2001 Mar;31(2-3):111-118 401.Fagerstrom K, Boyle P, Kunze M and Zatonski W. The anti-smoking climate in EU countries and Poland. Lung Cancer. 2001 Apr;32(1):1-5. 402.Franceschi S, Dal Maso L, Augustin L, Negri E, Parpinel M, Boyle P, Jenkins DJ, La Vecchia C. Dietary glycemic load and colorectal cancer risk. Ann Oncol. 2001 Feb;12(2):173-8. 403.Meuleman EJ, Donkers LH, Robertson C, Keech M, Boyle P, Kiemeney LA. Ned Tijdschr Geneeskd. 2001 Mar 24;145(12):576-81. Dutch. 404.Boyle P, Gandini S, Baglietto S, Severi G and Robertson C. Epidemiology of Prostate Cancer. European Urology 2001: 39: 2-3. 405.Sasieni P, Cuzick J, Boyle P, Hince T, Kitchener H, Lilleyman J, McEwen J, Miles R, Roche M, Slevin MM, Vessey M, Wald N, Wilkins N and Young N. Routine audit is an ethical requirement of screening . Brit Med J 2001; 322:1179. 406.Zheng T, Holford TR, Mayne ST, Owens PH, Zhang Y, Zhang B, Boyle P, Zahm SH. Lactation and breast cancer risk: a case-control study in Connecticut. Br J Cancer 2001 Jun;84(11):1472-6. 407.Boyle P, Leon M, Autier P. Epidemiology of Osteoporosis. J Epidemiol Biostat 2001;6(2):185-92. 408.Levi F, La Vecchia C, Boyle P, Lucchini F, Negri E. Western and eastern European trends in testicular cancer mortality. Lancet 2001 Jun 9;3 57 (9271):1853-4. 409.Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001 Sep 15;358(9285):861-5 410.Giles GG, Severi G, McCredie MR, English DR, Johnson W, Hopper JL, Boyle P. Smoking and prostate cancer: findings from an Australian case-control study. Ann Oncol 2001 C: Users fourneraj Documents PB 2013-06 PB CV.doc 411.Robertson C, Van Den Donk M, Primic-Zakelj M, MacFarlane T and BoyleP. The association between induced and spontaneous abortion and risk of breast cancer in Slovenian women aged 25-54. The Breast 2001; 10: 291-198. 412.Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D, Severi G, Robertson C, Boyle P. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001 Sep;58(3):417-24 413.Boyle P, Robertson C, Manski R, Padley RJ, Roehrborn CG. Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology 2001 Nov; 58 414.Roehrborn CG, Bartsch G, Kirby R, Andriole G, Boyle P, de la Rosette J, Perrin P, Ramsey E, Nordling J, De Campos Freire G, Arap S. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology 2001 Nov;58 (5):642-50 415.Levi F, Lucchini F, Negri E, Boyle P and La Vecchia C. Changed trends of cancer mortality in the elderly. Annals Oncology 2001; 12: 1467-1477. 416.Boyle P and Zheng T. Environmental factors influencing the epidemiology of breast cancer. The Breast 2001; 10 (supp 3): 1-8. 417.Plesko I, Severi G, Obsitnikova A, Boyle P and Kubik A. Lung cancer incidence rates by histologic type: an example of trends in Eastern Europe--Slovakia 1978-95. Neoplasma. 2001;48(4):247-53. 418.Collaborative Group on Hormonal Factors in Breast Cancer (includes P Boyle). Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001 Oct 27;358(9291):1389-99 419.Fourcade RO, Chauvin I, Gaudin AF, Mazzetta C, Boyle P. [Frequency of Nocturia in Auxerre, France: the UrEpiK study]. Prog Urol 2001;11(6):1251-8. 420.Fourcade RO, Gaudin AF, Mazzetta C, Robertson C, Boyle P. [Prevalence of LUTS and Incontinence in the Auxerre, France: the UrEpiK study]. Presse Med 2002;31(5):202-10 421.Gray N and Boyle P. Regulation of cigarette emissions. Ann Oncol 2002 Jan;13(1):19-21 422.Boyle P. Faecal occult blood testing (FOBT) as screening for colorectal cancer: the current controversy. Ann Oncol 2002 Jan;13(1):6-8 423.Parle JV, Maisonneuve P, Sheppard MC, Boyle P and Franklyn JA. Mortality in elderly patients with subclinical hypertension. Lancet 2002 Mar 2;359(9308):799 C: Users fourneraj Documents PB 2013-06 PB CV.doc 424.Veronesi U, Maisonneuve P., Sacchini V., Rotmensz N., Boyle P Tamoxifen for breast cancer among hysterectomised women. Lancet 2002; 359: 1122-4. 425.Filippini G, Maisonneuve P, McCredie M, Peris-Bonet R, Modan B, Preston-Martin S, Mueller BA, Holly EA, Cordier S, Choi NW, Little J, Arslan A, Boyle P. Relation of childhood brain tumors to exposure of parents and children to tobacco smoke: The Search international case-control study. Int J Cancer. 2002 Jul 10;100(2):206-13. 426.Debruyne F, Koch G, Boyle P, Da Silva FC, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela-Navarrete R, Raynaud JP. Comparison of a Phytotherapeutic Agent (Permixon) with an alpha-Blocker (Tamsulosin) in the Treatment of Benign Prostatic Hyperplasia: A 1-Year Randomized International Study. Eur Urol. 2002 May;41(5):497-507. 427.Giles GG, Severi G, Sinclair R, English DR, McCredie MR, Johnson W, Boyle P, Hopper JL. Related Articles Androgenetic alopecia and prostate cancer: findings from an Australian case-control study. Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):549-53. 428.Collaborative Group on Hormonal Factors in Breast Cancer (includes P Boyle). Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002 Jul 20;360(9328):187-95. 429.Zheng T, Holford TR, Mayne ST, Owens PH, Boyle P, Zhang B, Zhang YW, Zahm SH. Use of hair colouring products and breast cancer risk. a case-control study in Connecticut. Eur J Cancer 2002 Aug;38(12):1647-52 430.Levi F, Lucchini F, Negri E, Boyle P, Vecchia CL. Trends in mortality from Hodgkin's disease in western and eastern Europe. Br J Cancer 2002 Jul 29;87(3):291-3 431.Debruyne F, Koch G, Boyle P, Da Silva FC, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela-Navarrete R, Raynaud JP; groupe d'etude PERMAL. [Comparison of a Phytotherapeutic Agent (Permixon) with an alpha-Blocker (Tamsulosin) in the Treatment of Benign Prostatic Hyperplasia: A 1-Year Randomized International Study][In French] : Prog Urol 2002 Jun;12(3):384-92 432.Zheng T, Holford TR, Taylor Mayne S, Luo J, Hansen Owens P, Hoar Zahm S, Zhang B, Zhang Y, Zhang W, Jiang Y and Boyle P. A case-control study of occupation and breast- cancer risk in Connecticut. J Cancer Epidemiol Prev. 2002;7(1):3-11. 433.Roehrborn C, Boyle P, Nickel J, Hoefner K and Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002 Sep;60(3):434. 434.Zheng T, Holford TR, Zahm SH, Owens PH, Boyle P, Zhang Y, Wise JP Sr, Stephenson LP and Ali-Osman F. Cigarette smoking, glutathione-s-transferase M1 and t1 genetic polymorphisms, and breast cancer risk (United States). Cancer Causes Control. 2002 Sep;13(7):637-45. C: Users fourneraj Documents PB 2013-06 PB CV.doc 435.Rotmensz N, Decensi A, Maisonneuve P, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Lovison F, Gucciardo G, Muraca MG, Pizzichetta MA, Conforti S, Robertson C, Boyle P, Veronesi U.Rationale for a study adding tamoxifen to HRT. Eur J Cancer. 2002 Sep;38(S6):22-23 436.Boyle P. Current Situation of Screening for Cancer. Ann Oncol. 2002;13 Suppl 4:189-98. 437.Collaborative Group on Hormonal Factors in Breast Cancer (includes P Boyle). Alcohol, tobacco and breast cancer - collaborative reanalysis of individual data from 53 epidemiological studies, including 58 515 women with breast cancer and 95 067 women without the disease. Brit J Cancer 2002; 87: 1234-1246. 438.La Vecchia C, Bruzzi P, Decarli A, Gaboardi F, Boyle P. An estimate of prostate cancer prevalence in Italy. Tumori 2002 Sep-Oct;88(5):367-9. 439.Veronesi U, Maisonneuve P, Rotmensz N, Boyle P Tamoxifen for breast cancer in hysterectomised women. : Lancet 2002;360(9347):1785 440.Boyle P, Leon ME. Epidemiology of colorectal cancer. Br Med Bull 2002;64:1-25 441.Trabattoni D, Bartorelli AL, Montorsi P, Fabbiocchi F, Loaldi A, Galli S, Ravagnani P, Cozzi S, Grancini L, Liverani A, Leon ME, Robertson C, Boyle P. Comparison of outcomes in women and men treated with coronary stent implantation. Catheter Cardiovasc Interv 2003 442.Stewart JH, Buccianti G, Agodoa L, Gellert R, McCredie MR, Lowenfels AB, Disney AP, Wolfe RA, Boyle P, Maisonneuve. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 2003 Jan;14(1):197-207 443.Giles GG, Severi G, English DR, McCredie MR, MacInnis R, Boyle P, Hopper JL. Early growth, adult body size and prostate cancer risk. : Int J Cancer 2003 Jan 10;103(2):241-5 444.Veronesi U, P Maisonneuve, N Rotmensz, A Costa, V Sacchini, R Travaglini, G D'Aiuto, F Lovison, G Gucciardo, MG Muraca, MA Pizzichetta, S Conforti, A Decensi, C Robertson and P Boyle on behalf of the Italian Tamoxifen Study group. Tamoxifen and the prevention of hormonally dependent breast cancer in higher risk women : The Italian Randomized Trial Among Hysterectomized Women. J Natl Cancer Inst 2003; 95: 160-165. 445.Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S and Boyle P. Overview of main Outcomes in Breast Cancer Prevention Trials. Lancet 2003; 361: 296-300. 446.Boyle P. Screening. Eur J Respirator Disease 2003 ; 21: 3s-16s 447.Zheng T, Holford TR, Zahm SH, Owens PH, Boyle P, Zhang Y, Zhang B, Wise JP, Stephenson LR and Ali-Osman F. Glutathione S-transferase M1 and T1 genetic polymorphisms, alcohol consumption and breast cancer risk. Brit J Cancer 2003; 88: 58-62. C: Users fourneraj Documents PB 2013-06 PB CV.doc 448.Kirby R.S., Altwein J.E., Bartsch G., Boyle P., Jardin A., Roehrborn C., Cary M.M., Sweeney M., Grossman E.B. The Efficacy and Tolerability of Doxazosin and Finasteride, Alone or in combination, in the Treatment of Symptomatic Benign Prostatic Hyperplasia: Results of the Prospective European Doxazosin and Comination Therapy (PREDICT) Trial. Urology 2003 Jan;61(1):119-26. 449.Boyle P, Golia S, Daly P, Johnston P and Robertson C. Cancer Mortality in Ireland. Ann Oncol 2003;14:323-32. 450.Levi F, Lucchini F, Negri E, Boyle P and La Vecchia C. Mortality from major cancer sites in the European Union, 1955-1998. Ann Oncol 2003 Mar;14(3):490-5 451.Levi F, Lucchini F, Boyle P, Negri E and La Vecchia C. Testicular Cancer Mortality in Eastern Europe. Int J Cancer 2003 (Jul 1);105(4):574 452.Levi F, Lucchini F, Negri E, Boyle P and La Vecchia C. Recent trends in mortality from benign prostatic hyperplasia. The Prostate 2003 Aug 1;56(3):207-11. 453.Boyle P, Severi G and Giles GG. Epidemiology of Prostate Cancer. Urol. Clinics North America 2003 May;30(2):209-17. 454.Boyle P. Global Summit on Mammographic Screening. (Editorial) Annals Oncology 2003 Aug;14(8):1159-60. 455.Giles GG, Severi G, English DR, McCredie MRE, Borland R, Boyle P and Hopper JL. Sexual factors and prostate cancer. BJU Int 2003; 92: 211-216. 456.Severi G, Giles GG, Southey MC, Tesoriero A, Tilley W, Nufing, Morris H, English DR, McCredie MRE, Boyle P and Hopper JL. No association between ELAC2/HPC2 polymorphisms and serum prostate-specific antigen level or prostate cancer. J Natl Cancer Inst 2003 Jun 457.Boyle P Screening for Prostate Cancer - Have you had your cholesterol measured? BJU Int 2003; 92: 191-200. 458.Boyle P, d'Onofrio A, Maisonneuve P, Severi G, Robertson C, Tubiana M and Veronesi U. Measuring Progress Against Cancer In Europe: Has the 15% Decline targeted for 2000 come about? Annals Oncology 2003; 14: 1312-1325. 459.Boyle P, Autier P, Bartelink H, Baselga J, Boffetta P, Burn J, Burns HJG, Christensen L, Denis L, Dicato M, Diehl V, Doll R, Franceschi S, Gillis CR, Gray N, Gricuite L, Hackshaw A, Kasler M, Kogevinas M, Kvinnsland S, La Vecchia C, Levi F, McVie JG, Maisonneuve P, Martin-Moreno JM, Newton Bishop J, Oleari F, Perrin P, Richards M, Ringborg U, Siracka E, Quinn M, Storm H, Tubiana M, Tursz T, Veronesi U, Wald N, Weber W, Zaridze DG, Zatonski W and zur Hausen H. European Code Against Cancer and Scientific Justification: Third Version (2003). Annals Oncol 2003; 14: 973-1005. C: Users fourneraj Documents PB 2013-06 PB CV.doc 460.Quinn MJ, d'Onofrio A, Møller B, Black R, Martinez-Garcia C, Møller H, Rahu M, Robertson C, Schouten L, La Vecchia C and Boyle P. Cancer Mortality Trends in the EU and Acceeding States up to 2015. Annals Oncol 2003; 14: 1148-1152. 461.O'Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P and Hofner K. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha- reductase inhibitor. BJU Int. 2003 Aug;92(3):262-266 462.Autier P, Boyle P, Buyse M, Bleiberg H. Is FOB screening really the answer for lowering mortality in colorectal cancer? Recent Results Cancer Res. 2003;163:254-63 463.Veronesi U, Maisonneuve P, Rotmensz N, Decensi A, Viale G and Boyle P. Re: Italian Randomized Trial Among Women with Hysterectomy: Tamoxifen and Hormone-Dependent Breast Cancer in High-Risk Women. The Authors Response. J Natl Cancer Inst 2003; 95: 918-919 464.Pastorino U, Bellomi M, Landoni C, DE Fiori E, Arnaldi P, Picchio M, Pelosi G, Boyle P and Fazio F. Early lung-cancer detection with spiral CT and positron emission tomography: two years results. Lancet 2003; 362: 593-597. 465.Boyle P and Fitzpatrick JM. Prevalence of Benign Urological Disease in Communities. BJU Int. 2003 Sep;92(4):342-3 466.Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs R, Fourcade R, Kiemeney L, Lee C and the UrEpiK Study Group. The prevalence of lower urinary tract symptoms in men and women in four centres. The UREPIK study. BJU Int. 2003 Sep;92(4):409-414 467.Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs R, Fourcade R, Kiemeney L, Lee C and the UrEpiK Study Group. The relationship between lower urinary tract symptoms and health status The UREPIK study. BJU Int. 2003 Oct;92(6):575-580. 468.Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs R, Fourcade R, Kiemeney L, Lee C and the UrEpiK Study Group. The association between Lower Urinary Tract Symptoms and Erectile Dysfunction across four centers. The UREPIK study. BJU Int. 2003 Nov;92(7):719-725. 469.Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs R, Fourcade R, Kiemeney L, Lee C and the UrEpiK Study Group. The prevalence of male urinary incontinence across four centres The UREPIK study. BJU Int. 2003 Dec;92(9):943-947 470.Boyle P, Diehm C and Robertson C. Meta-analysis of Clinical Trials of Cyclo 3 Fort in the Treatment of Chronic Venous Insufficiency. Int Angiol. 2003 Sep;22(3):250-62 471.Gray N and Boyle P. The Future of the Nicotine Addiction Market. (Commentary) Lancet 2003 Sep 13;362(9387):845-6. 472.Boyle P. Tobacco control, screening, and collaboration are priorities for IARC, incoming director says. Interview with Peter Boyle. J Natl Cancer Inst. 2003 Nov 19;95(22):1653-5 C: Users fourneraj Documents PB 2013-06 PB CV.doc 473.Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O'Leary MJ, Puppo P, Robertson C and Giuliano F. Lower Urinary Tract Symptoms and Male Sexual Dysfunction: The Multinational Survey of the Ageing Male (MSAM-7). Eur Urol 2003; 44(6): 637-649. 474.Boyle P. Mammographic Screening: after the dust has settled. Breast. 2003 Dec;12(6):351- 475.Boyle P. Recommendation for mammographic screening after the dust settles. Breast. 2003 Mar;12 Suppl 1:S3. 476.Boyle P, Leon ME, Maisonneuve P and Autier P. Cancer Control In Women: Update 2003. Int J Gynaecol Obstet 2003 Oct;83 Suppl 1:179-202. 477.Morton LM, Holford TR, Leaderer B, Boyle P, Zham SH, Zhang Y, FlynnS, Tallini G, Zhang B, Owens P and Zheng T. Cigarette smoking and risk of non-Hodgkin Lymphoma subtypes among women. Brit J Cancer 2003; 89: 2087-2092. 478.Morton LM, Holford T, Leaderer B, Boyle P, Zahm SH, Zhang Y, Flynn F, Tallini G, Owens PH, Zhang B, Zheng T. Alcohol Use and risk of non-Hodgkin Lymphoma among Connecticut women. Cancer Causes Control 2003 Sep;14(7):687-94. 479.Boyle P. Testicular Cancer: The Challenge for Cancer Control. Lancet Oncology 2004; 5: 56- 480.Boyle P, Dore JF, Autier P and Ringborg U. Cancer of the Skin: A Forgotten Problem in Europe. Annals Oncology 2004; 15(1): 5-6. 481.Hodge A, English D, McCredie M, Severi G, Boyle P, Hopper JL and Giles GG. Foods, nutrients and prostate cancer. Cancer Causes Control. 2004 Feb;15(1):11-20. 482.Gray NE and Boyle P. The Case of the Disappearing Nitrosamines. A Potentially Global Phenomenon. Tobacco Control. 2004 Mar;13(1):13-6. 483.Zheng T, Holford T, Leaderer B, Zhang Y, Boyle P, Zahm SH, Flynn S, Tallini G, Zhang B, Zhou K, Owens PH, Rothman R, Lan Q and Boyle, P. Diet and nutrient intakes and risk of non-Hodgkin Lymphoma in Connecticut women. Am J Epidemiol. 2004 Mar 1;159(5):454-66. 484.Zhang Y, Holford TR, Leaderer B, Boyle P, Zahm SH, Flynn S, Tallini G, Owens PH and Zheng T. Hair Coloring Product Use And Risk of Non-Hodgkin's Lymphoma: A Population- based Case-Control Study In Connecticut. Amer J Epid 2004; 159: 148-154. 485.Morton LM, Engels EA, Holford TR, Leaderer B, Zhang Y, Zahm SH, Boyle P, Zhang B, Flynn S, Tallini G, Owens PH, Zheng T. Hepatitis C virus and risk of non-Hodgkin lymphoma: a population-based case-control study among Connecticut women. Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):425-30. C: Users fourneraj Documents PB 2013-06 PB CV.doc 486.Zhang Y, Holford TR, Leaderer B, Zahm SH, Boyle P, Morton LM, Zhang B, Zou K, Flynn S, Tallini G, Owens PH and Zheng T. Prior Medical Conditions and Medication Use and Risk of Non-Hodgkin Lymphoma in Connecticut United States Women. Cancer Causes Control 2004; 487.Zhang Y, Holford TR, Leaderer B, Boyle P, Zahm SH, Owens PH, Morton M, Zhang B, Zou K, Flynn S, Tallini G, and Zheng T. Blood Transfusion and Risk of Non-Hodgkin's Lymphoma in Connecticut. Women. Am J Epidemiol 2004 Aug; 160(4): 325-30. 488.Zhang Y, Holford TR, Leaderer B, Boyle P, Zahm SH, Zhang B, Zou K, Morton LM, Owens PH, Flynn S, Tallini G and Zheng T. Menstrual and reproductive factors and risk of non- Hodgkin's lymphoma among Connecticut women. Am J Epidemiol. 2004 Oct 15;160(8):766-73. 489.Collaborative Group on Hormonal Factors in Breast Cancer (includes P Boyle). Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83 000 women with breast cancer from 16 countries. Lancet 2004; 363: 1007-16 490.Boyle P, Robertson C, Lowe F and Roehrborn C. Updated Meta analysis of Clinical trials of Permixon® in the treatment of Symptomatic Benign Prostatic Hyperplasia. BJUInt. 2004 Apr;93(6):751-6. 491.Morton LM, Holford T, Leaderer B, Boyle P, Zahm SH, Zhang Y, Flynn F, Tallini G, Owens PH and Zheng T. Hepatitis B virus and risk of non-Hodgkin's lymphoma: a population-based case-control study in Connecticut women. Int J cancer (in press). 492.Boyle P, Roehrborn C, Harkaway R, Logie J, de la Rosette J and Emberton M. 5-alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urology 2004; 45(5): 626-627. 493.Levi F, Lucchini F, Negri E, Boyle P and La Vecchia C. Cancer Mortality in Europe, 1995- 1999, and an overview of trends since 1960. Int J Cancer 2004 Jun 10;110(2):155-69. 494.Levi F, Lucchini F, Negri E, Boyle P and La Vecchia C. The leveling of Prostate Cancer Mortality in Western Europe. The Prostate 2004; 60(1): 46-52. 495.Debruyne F, Boyle P, Calais Da Silva F, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela- Navarrete R, Raynaud JP, Schulman CC. Evaluation of the Clinical Benefit of Permixon and Tamsulosin in Severe BPH Patients-PERMAL Study Subset Analysis. Eur Urol. 2004 Jun;45(6):773-80. 496.Horninger W, Berger A, Pelzer A, Klocker H, Oberaigner W, Schonitzer D, Severi G, Robertson C, Boyle P, Bartsch G. Screening for prostate cancer: updated experience from the tyrol study. Curr Urol Rep. 2004 Jun;5(3):220-5. 497.Boyle P, Mezzetti M, Vecchia CL, Franceschi S, Decarli A, Robertson C. Contribution of three components to individual cancer risk predicting breast cancer risk in Italy. Eur J Cancer Prev. 2004 Jun;13(3):183-191. C: Users fourneraj Documents PB 2013-06 PB CV.doc 498.Gnagnarella P, Parpinel M, Salvini S, Franceschi S, Palli D and Boyle P. The update of the Italian Food Composition Database. J Food Comp Analysis 2004, 17: 509-522. 499.Boyle P, Robertson C, Vaughan D and Fitzpatrick JM. Meta-analysis of Transurethral Needle Ablation (TUNA) for the treatment of symptomatic benign prostatic hyperplasia. BJUInt 2004 500.Gray N and Boyle P. Publishing tobacco tar measurements on packets. BMJ 2004 Oct 9; 329 (7470): 813-4. 501.Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O'Leary MP, Puppo P, Robertson C and Giuliano F. [Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging.male (MSAM-7)] Prog Urol. 2004 Jun;14(3):332-44. French. 502.Debruyne F, Boyle P, Calais da Silva F, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela- Navarrete R, Raynaud JP, Schulman C. [Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis] Prog Urol. 2004 Jun;14(3):326-31. French. 503.Levi F, Lucchini F, Negri E, Zatonski W, Boyle P and La Vecchia C. Trends in cancer mortality in the European Union and accession countries, 1980-2000. Ann Oncol. 2004 Sep;15(9):1425-31. 504.Robertson C. Runzi N, Idris N and Boyle P. Beyond Classical Meta Analysis: Can inadequately reported studies be included? Drug Discovery Today 2004; 9 (21): 924-931. 505.Creasman WT, Kohler MF, Odicino F, Maisonneuve P and Boyle P. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol. 2004 Dec;95(3):593-6. 506.Zhang Y, Wise JP, Holford TR, Xie H, Boyle P, Zahm SH, Rusiecki J, Zou K, Zhang B, Zhu Y, Owens PH and Zheng T. Serum Polychlorinated Biphenyls, Cytochrome P-450 1A1 Polymorphisms, and Risk of Breast Cancer in Connecticut Women. Am J Epidemiol. 2004 Dec 15;160(12):1177-83. 507.Vandoninck V, Bemelmans BL, Mazzetta C, Robertson C, Keech M, Boyle P and Kiemeney LA. The prevalence of urinary incontinence in community-dwelling married women: a matter of definition. BJU Int. 2004 Dec;94(9):1291-5 508.Boyle P, Vainio H, Smith R, Benamouzig R, Lee WC, Segnan N, Takima K and Tsubono Y.Workgroup I: criteria for screening. UICC International Workshop on Facilitating Screening for Colorectal Cancer, Oslo, Norway (29 and 30 June 2002). Ann Oncol. 2005 Jan;16(1):25-30. C: Users fourneraj Documents PB 2013-06 PB CV.doc 509.Gandini S, Sera F, Cattaruzza MS, Picconi O, Boyle P and Melchi CF. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005 Jan;41(1):28-44. 510.Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P and Melchi CF. Meta- analysis of risk factors for cutaneous melanoma: II Sun exposure. Eur J Cancer. 2005 Jan;41(1):45-60. 511.Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C, Boyle P and Melchi CF. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer. 2005 Aug 24 512.Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, Salvioni A, Travaglini R, Oliviero P, D'Aiuto G, Gulisano M, Gucciardo G, Del Turco MR, Pizzichetta MA, Conforti S, Bonanni B, Boyle P and Veronesi U. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial Circulation. 2005 Feb 8;111(5):650-6. 513.Veronesi U, Boyle P, Goldhirsch A, Orrechia R and Viale G. Seminar on Breast Cancer. Lancet. 2005 May 365 (9472):1727-41. 514.Boyle P and Ferlay J. Cancer incidence and mortality in Europe, 2004. Annals Oncol 2005; 515.Boyle P. Tobacco Smoking and British Doctors' Cohort (Editorial). Brit J Cancer 2005; 92: 516.Kreimer AR, Clifford GM, Boyle P and Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol. Biomarkers Prev. 2005; 14(2): 467-75. 517.Horninger W, Berger A, Pelzer A, Klocker H, Oberaigner W, Schonitzer D, Severi G, Robertson C, Boyle P and Bartsch G. Screening for prostate cancer: updated experience from the Tyrol study. Can J Urol. 2005 Feb;12 (1 Supp1):7-13. 518.Bruno S, Maisonneuve P, Castellana P, Rotmensz N, Rossi S, Maggioni M, Persico M, Colombo A, Monasterolo F, Casadei-Giunchi D, Desiderio F, Stroffolini T, Decensi A, Veronesi U and the Italian Tamoxifen Study Group (includes Boyle P). Incidence and Risk Factors for non-alcoholic steatohepatitis in the Italian Tamoxifen Chemoprevention Trial BMJ 2005; 21st March 2005. 519.Gray N, Henningfield JE, Benowitz NL, Connolly GN, Dresler C, Fagerstrom K, Jarvis MJ and Boyle P. Toward a comprehensive long term nicotine policy. Tob Control. 2005 Jun;14(3):161-5. C: Users fourneraj Documents PB 2013-06 PB CV.doc 520.Boyle P, Ariyaratne M, Bartelink H, Baselga J, Berns A, Brawley OW, Burns H, Davidov M, Dinshaw K, Dresler C, Eggermont AM, Gajurel D, Gordina G, Gray N, Kakizoe T, Karki BS, Kásler M, Kerr DJ, Khayat D, Kiselev A, Khuhaprema T, Klocker H, Levshin V, Martin-Moreno JM, McVie JG, Mendelsohn J, Napalkov NP, Ngoma TA, Park JG, Philip T, Pötschke-Langer M, Poudal HN, Rajan B, Ringborg U, Rodger A, Seffrin JR, Shanta V, Shrestha MM, Thomas R, Tursz T, de Valeriola D, Veronesi U, Wiestler OD, Zaridze D, Zatonski W and Zeng YX. Curbing tobacco's toll starts with the professionals: World No Tobacco Day. The Lancet (11th June) 2005; 365: 1990-1992 521.Scully C and Boyle P. The role of the dental team in preventing and diagnosing cancer; 1. Cancer in general. Dent Update. 2005 May;32(4):204-6, 208-10, 212. 522.Boyle P and Ferlay J. Mortality and survival in breast and colorectal cancer. Nature Clinical Practice Oncology (2005) 2, 424-425 523.Cogliano VJ, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi and Boyle P. Transparency in the IARC Monographs. Lancet Oncology 2005; 6: 747. 524.Boyle P and Dresler C. Preventing the lung cancer epidemic. Annals Oncology 2005; 16: 525.Zhang Y, Lan Q, Rothman N, Zhu Y, Zahm SH, Wang SS, Holford TR, Leaderer B, Boyle P, Zhang B, Zou K, Chanock S and Zheng T. A putative exonic splicing polymorphism in the BCL6 gene and the risk of non-Hodgkin lymphoma. J Natl Cancer Inst. 2005 Nov 2;97(21):1616-8. 526.Veronesi U and Boyle P. Breast cancer – Authors' reply. The Lancet 366 (9497): 1606. 527.Boyle P. Breast cancer control: Signs of progress, but more work required. Breast 2005 Dec;14(6):429-38. 528.Baglietto L, Jenkins MA, Severi G, Giles GG, Bishop DT, Boyle P and Hopper JL. Measures of familial aggregation depend on definition of family history: meta-analysis for colorectal cancer. J Clin Epidemiol 2006 Feb;59(2):114-124. 529.Severi G, Morris HA, Macinnis RJ, English DR, Tilley W, Hopper JL, Boyle P and Giles GG. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):86-91 530.Zhu Y, Zheng T, Stevens RG, Zhang Y and Boyle P. Does "clock" matter in prostate cancer? Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):3-5. 531.Lan Q, Zheng T, Rothman N, Zhang Y, Wang SS, Shen M, Berndt SI, Zahm SH, Holford TR, Leaderer B, Yeager M, Welch R, Boyle P, Zhang B, Zou K, Zhu Y and Chanock S. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood. 2006 Jan 31; [Epub ahead of print] PMID 16639601 C: Users fourneraj Documents PB 2013-06 PB CV.doc 532.Zatonski W, Mikucka M, La Vecchia C and Boyle P. Infant mortality in Central Europe: effects of transition. Gac Sanit. 2006 Jan-Feb;20(1):63-6. 533.Cardis E, Krewski D, Boniol M, Drozdovitch V, Darby SC, Gilbert ES, Akiba S, Benichou J, Ferlay J, Gandini S, Hill C, Howe G, Kesminiene A, Moser M, Sanchez M, Storm H, Voisin L and Boyle P. Estimates of the cancer burden in Europe from radioactive fallout from the Chernobyl accident. Int J Cancer. 2006 Apr 20; [Epub ahead of print] 534.Shen M, Zheng T, Lan Q, Zhang Y, Zahm SH, Wang SS, Holford TR, Leaderer B, Yeager M, Welch R, Kang D, Boyle P, Zhang B, Zou K, Zhu Y, Chanock S, Rothman N. Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut. Hum Genet. 2006 Jul;119(6):659-68. 535.Boyle P, Ariyaratne MA, Barrington R, Bartelink H, Bartsch G, Berns A, de Valeriola D, Dinshaw KA, Eggermont AM, Gray N, Kakizoe T, Karki BS, Kaslar M, Kerr DJ, Khayat D, Khuhaprema T, Kim IH, Martin-Moreno J, McVie G, Park JG, Philip T, Ringborg U, Rodger A, Seffrin JR, Semiglazov V, Soo KC, Sun YT, Thomas R, Tursz T, Veronesi U, Wiestler O, Yoo KY, Zatonski W and Zhao P. Tobacco: deadly in any form or disguise. Lancet. 2006 May 27;367(9524):1710-2. 536.Severi G, Hayes VM, Neufing P, Padilla EJ, Tilley WD, Eggleton SA, Morris HA, English DR, Southey MC, Hopper JL, Sutherland RL, Boyle P and Giles GG. Variants in the prostate- specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA. Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1142-7. 537.Severi G, Morris HA, MacInnis RJ, English DR, Tilley WD, Hopper JL, Boyle P and Giles GG. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1137-41. 538.Boyle P. The Globalisation of Cancer. Lancet 2006; 368: 629-630 539.Lan Q, Zheng T, Chanock S, Zhang Y, Shen M, Wang SS, Berndt SI, Zahm SH, Holford TR, Leaderer B, Yeager M, Welch R, Hosgood D, Boyle P and Rothman N. Genetic variants in caspase genes and susceptibility to non-Hodgkin lymphoma. Carcinogenesis. 2007; 28(4): 823-827. 540.Zhu Y, Leaderer D, Guss C, Brown HN, Zhang Y, Boyle P, Stevens RG, Hoffman A, Qin Q, Han X and Zheng T. Ala394Thr polymorphism in the clock gene NPAS2: A circadian modifier for the risk of non-Hodgkin's lymphoma. Int J Cancer. 2007 (Jan 15); 120(2) :432-5. 541.Hayes VM, Severi G, Padilla EJ, Morris HA, Tilley WD, Southey MC, English DR, Sutherland RL, Hopper JL, Boyle P and Giles GG. 5-alpha-reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. Int J Cancer 2007; 120(4): 776-780. 542.Lan Q, Zheng T, Shen M, Zhang Y, Wang SS, Zahm SH, Holford TR, Leaderer B, Boyle P and Chanock S. Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma. Hum Genet. 2007; 28(4): 823-7. C: Users fourneraj Documents PB 2013-06 PB CV.doc 543.Zhang Y, Wang R, Holford TR, Leaderer B, Zahm SH, Boyle P, Zhu Y, Qin Q and Zheng T. Family history of hematopoietic and non-hematopoietic malignancies and risk of non- Hodgkin lymphoma. Cancer Causes Control. 2007; 18(4): 351-359. 544.Ferlay J, Autier P, Boniol M, Heanue M, Colombet M and Boyle P. Estimates of cancer incidence and mortality in Europe in 2006. Annals Oncology 2007; 18(3): 581-592. 545.Zhang Y, Holford TR, Leaderer B, Boyle P, Zhu Y, Wang R, Zou K, Zhang B, Wise JP Sr, Qin Q, Kilfoy B, Han J and Zheng T. Ultraviolet Radiation Exposure and Risk of Non-Hodgkin's Lymphoma. Am J Epidemiol. 2007; 165(11): 1255-1264. 546.Robertson C, Link CL, Onel E, Mazzetta C, Keech M, Hobbs R, Fourcade R, Kiemeney L, Lee C, Boyle P and McKinlay JB. The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies. BJU Int. 2007 Feb;99(2):347-54. 547.Boffetta P, McLaughlin JK, La Vecchia C, Autier P and Boyle P. "Environment" in cancer causation and aetiological fraction: Limitations and ambiguities. Carcinogenesis 2007; 28(5): 548.Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Oliviero P, Lovison F, Gucciardo G, del Turco MR, Muraca MG, Pizzichetta MA, Conforti S, Decensi A; Italian Tamoxifen Study Group. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst. 2007 May 2;99(9):727-37. 549. Scully C, Boyle P, Day T, Hill B, Joshi V, Leupold NE, Shah JP and Lefebvre JL. International Consortium on Head and Neck Cancer Awareness (ICOHANCA). Oral Oncol 2007: Oct;43(9):841-842. 550.Boyle P. Book Review: Conspiracy theories of cancer, Lancet 2007; 370: 1751 551.Ferlay J, Randi G, Bosetti C, Levi F, Negri E, Boyle P, La Vecchia C. Declining mortality from bladder cancer in Europe. BJU Int. 2008; 101(1): 11-19. 552.Severi G, Hayes VM, Tesoriero AA, Southey MC, Hoang HN, Padilla EJ, Morris HA, English DR, Sutherland RL, Boyle P, Hopper JL, Giles GG. The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels. BJU Int. 2008; 101(4): 492-6. 553.Koutros S, Zhang Y, Zhu Y, Mayne ST, Zahm SH, Holford TR, Leaderer BP, Boyle P, Zheng T. Nutrients Contributing to One-Carbon Metabolism and Risk of Non-Hodgkin Lymphoma Subtypes. Am J Epidemiol. 2008 Feb 1; 167(3): 287-94 554.Hainaut P and Boyle P. Curbing the Liver Cancer Epidemic in Africa. Lancet 2008; 371(9610): 367-368. C: Users fourneraj Documents PB 2013-06 PB CV.doc 555.Gandini S, Botteri E, Iodice S, Boniol M, Lowenfels AB, Maisonneuve P and Boyle P. Tobacco smoking and cancer: A meta-analysis. Int J Cancer. 2008 Jan 1;122(1):155-64. 556.Levi F, Ferlay J, Galeone C, Lucchini F, Negri E, Boyle P and La Vecchia C. The changing pattern of Kidney Cancer incidence and mortality in Europe. BJU Int. 2008 Apr;101(8):949- 557.Autier P and Boyle P. Artificial ultraviolet sources and skin cancers: rationale for restricting access to sunbed use before 18 years of age. Nat Clin Pract Oncol 2008; 5(4): 178-9. 558.Bartsch G, Horninger W, Klocker H, Pelzer A, Bektic J, Oberaigner W, Schennach H, Schafer G, Frauscher F, Boniol M, Severi G, Robertson C and Boyle P on behalf of the Tyrol Prostate Cancer Screening Group. Tyrol Prostate Cancer Demonstration Project: Early Detection, Treatment, Outcome, Incidence and Mortality.BJU Int. 2008 Apr;101(7):809-16. 559.Boyle P. Favourable trends in cancer mortality in the European Union but no room for complacency. Annals Oncol 2008; 19: 605-606 560.Lingwood R, Boyle P, Milburn A, Arbuthnott J, McCaffrey R, Kerr SH and Kerr DJ. The Challenge of Cancer Control in Africa. Nature Rev Cancer 2008; 8(5): 398-403. 561.Park JG, Park JW, Kim DW, Seo HG, Nam BH, Lee JS, Choi JC, Kim IS and Boyle P. Factors influencing attitudes to legislation banning the manufacture and sale of tobacco products. Tob Control. 2008 Apr;17(2):142-3 562.Boyle P, Anderson B, Andersson LC, Ariyatne Y, Auleley G-R, Barbacid M, Bartelink H, Baselga J, Behbehani K,, Belardelli F, Berns A, Bishop J, Brawley O, Burns HJG, Clanton M, Cox B, Currow D, Dangou J-M, de Valeriola D, Dinshaw K, Eggermont A, Fitzpatrick JM, Forstmane M, Garaci E, Gavin AT, Kakizoe T, Kasler M, Keita N, Kerr DJ, Khayat D, Khleif S, Khuhaprema T, Knezevic T, Kubinova R, Mal ath M, Martin-Moreno JM, McCance D, McVie JG, Merriman A, Ngoma T, Nowacki M, Orgelbrand J, Park J-G, Pierotti M, Pinil os Ashton L, Puska P, Escobar CVR, Rajan B, Rajkumar T, Ringborg U, Robetson C, Rodger A, Roovali L, Santini LA, Sarhan M, Seffrin J, Semiglazov V, Shrestra BM, Soo KC, Stamenic V, Tamblyn C, Thomas R, Tuncer AM, Tursz T, Vaitkiene R, Val ejos C, Veronesi U, Wojtyla A, Yach D, Yoo K-Y, Zatonski W, Zaridze DG, Zeng Y-X, Zhao P and Zheng T. Need for Global Action for Cancer Control. Annals Oncology 2008; 19: 1519-1521. 563.Boffetta P, Tubiana M, Hill C, Boniol M, Aurengo A, Masse R, Valleron A-J, Monier R, de The G, Boyle P and Autier P. The Causes of Cancer in France. Annals Oncology 2008; (epub ahead of print) PMID 18765462 564.Boyle P, Boffetta P and Autier P. Diet, Nutrition and Cancer: Public, Media and Scientific Confusion. Annals Oncolgy 2008 Oct;19(10):1665-7. 565.Zhang Y, Guo GL, Han X, Zhu C, Kilfoy BA, Zhu Y, Boyle P and Zheng T. Do Polybrominated Diphenyl Ethers (PBDEs) Increase the Risk of Thyroid Cancer? Biosci Hypotheses. 2008;1(4):195-199 C: Users fourneraj Documents PB 2013-06 PB CV.doc 566.Wang R, Zhang Y, Lan Q, Holford TR, Leaderer B, Hoar Zahm S, Boyle P, Dosemeci M, Rothman N, Zhu Y, Qin Q and Zheng T. Occupational Exposure to Solvents and Risk of Non-Hodgkin Lymphoma in Connecticut Women. Am J Epidemiol. 2008 Dec 4. [Epub ahead of 567.Zaridze D, Maximovitch D, Lazarev A, Igitov V, Boroda A, Boreham J, Boyle P, Peto R and Boffetta P. Alcohol poisoning is a main determinant of recent mortality trends in Russia: evidence from a detailed analysis of mortality statistics and autopsies. Int J Epidemiol. 2009; 38(1):143-53. 568.Sun X, Huang J, Homma T, Kita D, Klocker H, Schafer G, Boyle P and Ohgaki H. Genetic Alterations in the PI3K Pathway in Prostate Cancer. Anticancer Res. 2009 May;29(5):1739- 569.Boyle P, Heanue M, Robertson C, Ferlay J, Gavin A, Fitzpatrick J and Johnson PG. Cancer in Ireland, 1926-2005. Annals Oncology (in press). 570.Boyle P and Brawley OW. Prostate Screening: Evidence Weighs Against Population Screening.CA Cancer J Clin 2009 [doi: 10.3322/caac.20025]epub ahead of print. 571.Duell EJ, Maisonneuve P, Baghurst PA, Bueno-de-Mesquita HB, Ghadirian P, Miller AB, Zatonski W, Vrieling A, Boffetta P and Boyle P. Menstrual and reproductive factors and pancreatic cancer in the SEARCH program of the IARC. Cancer Causes Control. 2009 Aug 4. [Epub ahead of print] 572.Kilfoy BA, Zheng T, Lan Q, Han X, Holford T, Hein DW, Qin Q, Leaderer B, Morton LM, Yeager M, Boyle P, Zhao P, Chanock S, Rothman N and Zhang Y. Genetic variation in N- acetyltransferases 1 and 2, cigarette smoking, and risk of non-Hodgkin lymphoma. Cancer Causes Control. 2009 Oct 7. [Epub ahead of print] 573.Ma S, Zhang Y, Huang J, Han X, Holford T, Lan Q, Rothman N, Boyle P and Zheng T. Identification of Non-Hodgkin's Lymphoma Prognosis Signatures Using the CTGDR Method. Bioinformatics. 2009 Oct 22. [Epub ahead of print]. 574.La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P and Levi F. Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Annals Oncology [published online November 30, 2009 doi:10.1093/annonc/mdp530] 575.Boyle P and Boffetta P. Alcohol consumption and breast cancer risk. Breast Cancer Research 2009;11 Suppl 3:S3. Epub 2009 Dec 18.[PMID: 20030878] 576.Han X, Zheng T, Foss FM, Ma S, Holford T, Boyle P, Leaderer B, Zhao P, Dai M and Zhang Y. Alcohol consumption and non-Hodgkin lymphoma survival. J Ca Survivorship 2009 Dec 29. [Epub ahead of print] 577.Boyle P, Ford I, Robertson J, La Vecchia C, Boffetta P and Autier P. Essential considerations in the investigation of associations between insulin and cancer risk using prescription databases. Ecancermedicalscience. 2009;3:174. Epub 2009 Dec 11. [PMID: 22276024] C: Users fourneraj Documents PB 2013-06 PB CV.doc 578.Maisonneuve P, Lowenfels AB, Bueno-de-Mesquita HB, Ghadirian P, Baghurst PA, Zatonski WA, Miller AB, Duell EJ, Boffetta P and Boyle P. Past Medical History and Pancreatic Cancer Risk: Results From a Multicenter Case-Control Study. Ann Epidemiol. 2010 Feb;20(2):92-98. 579.Kilfoy BA, Ward MH, Zheng T, Holford TR, Boyle P, Zhao P, Dai M, Leaderer B and Zhang Y. Risk of non-Hodgkin lymphoma and nitrate and nitrite from the diet in Connecticut women. Cancer Causes Control. 2010 Mar 5. [Epub ahead of print] 580.Boffetta P, Autier P, Boniol M, Boyle P, Hill C, Aurengo A, Masse R, de Thé G, Valleron AJ, Monier R and Tubiana M. An Estimate of Cancers Attributable to Occupational Exposures in France. J Occup Environ Med. 2010 Mar 30. [Epub ahead of print] 581.Conde L, Halperin E, Akers NK, Brown KM, Smedby KE, Rothman N, Nieters A, Slager SL, Brooks-Wilson A, Agana L, Riby J, Liu J, Adami HO, Darabi H, Hjalgrim H, Low HQ, Humphreys K, Melbye M, Chang ET, Glimelius B, Cozen W, Davis S, Hartge P, Morton LM, Schenk M, Wang SS, Armstrong B, Kricker A, Milliken S, Purdue MP, Vajdic CM, Boyle P, Lan Q, Zahm SH, Zhang Y, Zheng T, Becker N, Benavente Y, Boffetta P, Brennan P, Butterbach K, Cocco P, Foretova L, Maynadié M, de Sanjosé, S, Staines A, Spinelli JJ, Achenbach SJ, Call TG, Camp NJ, Glenn M, Caporaso NE, Cerhan JR, Cunningham JM, Goldin LR, Hanson CA, Kay NE, Lanasa MC, Leis JF, Marti GE, Rabe KG, Rassenti LZ, Spector LG, Strom SS, Vachon CM, Weinberg JB, Holly EA, Chanock S, Smith MT, Bracci PM and Skibola CF. Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet. 2010 Jul 18. [Epub ahead of print]. 582.Boyle P, Chapman CJ, Holdenrieder S, Murray A, Robertson C, Wood WC, Maddison P, Healey G, Fairley GH, Barnes AC and Robertson JF. Clinical validation of an autoantibody test for lung cancer. Ann Oncol. 2010 Jul 30. [Epub ahead of print] 583.Li Q, Zheng T, Holford TR, Boyle P, Zhang Y and Dai M. Light at night and breast cancer risk: results from a population-based case-control study in Connecticut, USA. Cancer Causes Control. 2010 Oct 7. [Epub ahead of print] 584.Chen Y, Zheng T, Lan Q, Foss F, Kim C, Chen X, Dai M, Li Y, Holford T, Leaderer B, Boyle P, Chanock SJ, Rothman N and Zhang Y. Cytokine polymorphisms in Th1/Th2 pathway, body mass index, and risk of non-Hodgkin lymphoma. Blood. 2010 Oct 15. [Epub ahead of print] 585.Boyle P and Howell A: The globalisation of breast cancer. Breast Cancer Research 2010, 586.Barry KH, Zhang Y, Lan Q, Zahm SH, Holford TR, Leaderer B, Boyle P, Hosgood HD 3rd, Chanock S, Yeager M, Rothman N and Zheng T. Genetic Variation in Metabolic Genes, Occupational Solvent Exposure, and Risk of Non-Hodgkin Lymphoma. Am J Epidemiol. 2011 Jan 12. [Epub ahead of print] PMID: 21228414 587.Pelucchi C, La Vecchia C, Bosetti C, Boyle P and Boffetta P. Exposure to acrylamide and human cancer--a review and meta-analysis of epidemiologic studies. Ann Oncol. 2011 Jan 13. [Epub ahead of print] PMID: 21239401 C: Users fourneraj Documents PB 2013-06 PB CV.doc 588.Boniol M, Doré JF and Boyle P. Re. Lehrer S, Green S, Stock RG (2011) Association between number of cell phone contracts and brain tumor incidence in nineteen U.S. States. J Neurooncol 101:505-507. 589.Smedby KE, Foo JN, Skibola CF, Darabi H, Conde L, Hjalgrim H, Kumar V, Chang ET, Rothman N, Cerhan JR, Brooks-Wilson AR, Rehnberg E, Irwan ID, Ryder LP, Brown PN, Bracci PM, Agana L, Riby J, Cozen W, Davis S, Hartge P, Morton LM, Severson RK, Wang SS, Slager SL, Fredericksen ZS, Novak AJ, Kay NE, Habermann TM, Armstrong B, Kricker A, Milliken S, Purdue MP, Vajdic CM, Boyle P, Lan Q, Zahm SH, Zhang Y, Zheng T, Leach S, Spinelli JJ, Smith MT, Chanock SJ, Padyukov L, Alfredsson L, Klareskog L, Glimelius B, Melbye M, Liu ET, Adami HO, Humphreys K, Liu J. GWAS of Follicular Lymphoma Reveals Allelic Heterogeneity at 6p21.32 and Suggests Shared Genetic Susceptibility with Diffuse Large B-cell Lymphoma. PLoS Genet 7(4): e1001378. doi:10.1371/journal.pgen.1001378 590.Lam S, Boyle P, Healey GF, Maddison P, Peek L, Murray A, Chapmand CJ, Allen J, Wood WC, Sewell HF and Robertson JF. EarlyCDT-Lung: An Immunobiomarker Test as an Aid to Early Detection of Lung Cancer. Cancer Prev Res 2011; 4(7): 1126-34 591.Bojar I, Bilinski P, Boyle P, Zatonski W, Marcinkowski J and Wojtyla A. Prevention of female reproductive system cancer among rural and urban Polish pregnant women. Ann Agric Environ Med. 2011 Jun;18(1):183-8. [PMID: 21736284] 592.Wojtyla A, Bojar I, Boyle P, Zatonski W, Marcinkowski J and Bilinski P. Nutritional behaviours among pregnant women from rural and urban environments in Poland. Ann Agric Environ Med. 2011 Jun;18(1):169-74. [ PMID:21736282] 593.Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, Khayat D, Boyle P, Autier P, Tannock IF, Fojo T, Siderov J, Williamson S, Camporesi S, McVie JG, Purushotham AD, Naredi P, Eggermont A, Brennan MF, Steinberg ML, De Ridder M, McCloskey SA, Verellen D, Roberts T, Storme G, Hicks RJ, Ell PJ, Hirsch BR, Carbone DP, Schulman KA, Catchpole P, Taylor D, Geissler J, Brinker NG, Meltzer D, Kerr D, Aapro M. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011 Sep;12(10):933-80. 594.Bassig BA, Zheng T, Zhang Y, Berndt SI, Holford TR, Hosgood HD 3rd, Hu W, Leaderer B, Yeager M, Menashe I, Boyle P, Xu J, Zou K, Zhu Y, Chanock S, Rothman N and Lan Q. Polymorphisms in complement system genes and risk of non-Hodgkin lymphoma. Environ Mol Mutagen. 2011 Dec 15. doi: 10.1002/em.21675. [Epub ahead of print] 595.Zhu G, Pan D, Zheng T, Lan Q, Chen X, Chen Y, Kim C, Bi X, Holford T, Boyle P, Leaderer B, Chanock SJ, Rothman N, Zhang Y. Polymorphisms in Th1/Th2 cytokine genes, hormone replacement therapy, and risk of non-Hodgkin lymphoma. Front Oncol. 2011 Jul 28;1(21). 596.Boyle P. Improving health in central and eastern europe. Ann Agric Environ Med. 2011 Dec C: Users fourneraj Documents PB 2013-06 PB CV.doc 597.Zatoński WA; Manczuk M, Sulkowska U, Didkowska J, Wojciechowska U, Tarkowski W, Przewozniak K, Gumkowski J, Janik-Koncewicz K, Boffetta P, Campos H, LaVecchia C, Powles J, Rehm J, Willet W, Negri E, Aaro L, Boyle P, Gilmore A, Jougla E, Moreno JM, Lowenfels A, Paccaud F, Peto R, Petric VK, Puska P, Klumbiene J, Pudule I, Kiivet R, Aaviksoo A, Albreht T, Kaposvari C, Dimitrov P, Holcatova I, Pilipcinova A, Poledne R, Marcinkova D, Furtunescu F, Bagnardi V, Baliunas D, Brozova J, Vrbanova H, Bene M, West R, Jarvis M, Bohm G, Kunze M, Gisle L, Joossens L, Storm H, Laatikainen T, Wilquin JJ, Ratte S, Thyrian R, Gallus S, Zeegers T, Prins T, Munoz EF, Karlsson AS, Halicka E, Lund J, Moskalewicz J, Patra J, Pavillon G, Popova S, Scotti L and Taylor B. Epidemiological analysis of health situation development in Europe and its causes until 1990. Ann Agric Environ Med. 2011 Dec;18(2):194-202. 598. Li Q, Holford TR, Zhang Y, Boyle P, Mayne ST, Dai M and Zheng T. Dietary fiber intake and risk of breast cancer by menopausal and estrogen receptor status. Eur J Nutr. 2012 Feb 16. [Epub ahead of print] 599.Zhang Y, Zhu C, Curado MP, Zheng T and Boyle P. Changing patterns of bladder cancer in the USA: evidence of heterogeneous disease. BJU Int. 2012 Jan;109(1):52-6. doi: 10.1111/j.1464-410X.2011.10283.x. Epub 2011, May 18 600.Kim C, Zheng TZ, Lan Q, Chen Y, Foss FM, Chen X, Holford TR, Leaderer B, Boyle P, Chanock SJ, Rothman N and Zhang Y. Genetic polymorphisms in oxidative stress pathway genes and modification of BMI and risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2012 Feb 28. [Epub ahead of print] 601.Aschebrook-Kilfoy B, Ward MH, Zheng T, Holford TR, Boyle P, Leaderer B and Zhang Y. Dietary Nitrate and Nitrite Intake and Non-Hodgkin Lymphoma Survival. Nutr Cancer. 2012 Mar 16. [Epub ahead of print] 602.Jiao J, Zheng T, Lan Q, Chen Y, Deng Q, Bi X, Kim C, Holford T, Leaderer B, Boyle P, Ba Y, Xia Z, Chanock SJ, Rothman N and Zhang Y. Occupational solvent exposure, genetic variation of DNA repair genes, and therisk of non-Hodgkin's lymphoma. Eur J Cancer Prev. 2012 Mar 17. [Epub ahead of print] 603.Largent J, Oefelein M, Kaplan HM, Okerson T and Boyle P. Risk of lymphoma in women with breast implants: analysis of clinical studies. Eur J Cancer Prev. 2012 May;21(3):274-80. 604.Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, Allen J, Thorpe AJ, Hamilton-Fairley G, Parsy-Kowalska CB, Macdonald IK, Jewell W, Maddison P and Robertson JF. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol. 2012 Apr 11. [Epub ahead of print] 605.Deng Q, Zheng T, Lan Q, Lan Y, Holford T, Chen Y, Dai M, Leaderer B, Boyle P, Chanock SJ, Rothman N and Zhang Y. Occupational solvent exposure, genetic variation in immune genes, and the risk for non-Hodgkin lymphoma. Eur J Cancer Prev. 2012 May 18. [Epub ahead of print] C: Users fourneraj Documents PB 2013-06 PB CV.doc 606.Bi X, Zheng T, Lan Q, Xu Z, Chen Y, Zhu G, Foss F, Kim C, Dai M, Zhao P, Holford T, Leaderer B, Boyle P, Deng Q, Chanock SJ, Rothman N and Zhang Y. Genetic polymorphisms in IL10RA and TNF modify the association between blood transfusion and risk of non- Hodgkin lymphoma. Am J Hematol. 2012 Apr 26. doi: 10.1002/ajh.23244. [Epub ahead of print] 607. Gandini S, Negri E, Boffetta P, La Vecchia C and Boyle P. Mouthwash and Oral Cancer Risk Quantitative Meta-analysis of Epidemiologic Studies. Ann Agric Environ Med. 2012 Jun 27;19(2):173-80. 608.Boniol M, Autier P, Boyle P and Gandini S. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ2012;345 doi: 10.1136/bmj.e4757(Published 609.Boyle P, Koechlin A, Pizot C, Boniol M, Robertson C, Mullie P, Bolli G, Rosenstock
J, Autier P. Blood glucose concentrations and breast cancer risk in women without
diabetes: a meta-analysis. Eur J Nutr. 2012 Nov 3. [Epub ahead of print][PMID: 23124254]

610.Boyle P, Boniol M, Koechlin A, Robertson C, Valentini F, Coppens K, Fairley LL,
Boniol M, Zheng T, Zhang Y, Pasterk M, Smans M, Curado MP, Mullie P, Gandini S,
Bota M, Bolli GB, Rosenstock J, Autier P. Diabetes and breast cancer risk: a meta-analysis.
Br J Cancer. 2012 Oct 23;107(9):1608-17. [PMID:22996614]
611.Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, Allen J, Thorpe
AJ, Hamilton-Fairley G, Parsy-Kowalska CB, Macdonald IK, Jewell W, Maddison P and
Robertson JF. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol. 2012 Oct;33(5):1319-26. [PMID: 22492236]
612.Boniol M, Boyle P, Autier P, Ruffion A, Perrin P. Critical role of prostate biopsy
mortality in the number of years oflife gained and lost within a prostate cancer screening programme. BJU Int. 2012 Sep 18. doi: 10.1111/j.1464-410X.2012.11513.x. [Epub ahead of print][PMID:22984785]
613.Boyle P. Triple-negative breast cancer: epidemiological considerations and
recommendations. Ann Oncol. 2012 Aug;23 Suppl 6:vi7-vi12. [PMID:23012306]
614.Zhu G, Foss F, Kim C, Dai M, Zhao P, Holford T, Leaderer B, Boyle P, Deng Q, Chanock SJ,
Rothman N, Zhang Y. Genetic polymorphisms in IL10RA and TNF modify the association between blood transfusion and risk of non-Hodgkin lymphoma. Am J Hematol. 2012 Aug;87(8):766-9. [PMID:22649007] 615.Lech-Maranda E, Bienvenu J, Broussais-Guillaumot F, Michallet AS, Warzocha K, Biliński P, Boyle P, Coiffier B, Salles G. Pretreatment Levels of Vascular Endothelial Growth Factor
in Plasma Predict a Complete Remission Rate and Time to Relapse or Progression in Patients with Diffuse Large B-Cell Lymphoma. Arch Immunol Ther Exp (Warsz). 2013 Jan 3. [Epub ahead of print] [PMID:23283519] C: Users fourneraj Documents PB 2013-06 PB CV.doc Mouthwash other Metformin Glargine meta Breast and Diabetes Glargine North Europe Glargine Methods Carbonated beverages C: Users fourneraj Documents PB 2013-06 PB CV.doc

Source: http://www.eurama.it/public/curriculum/cv-boyle.pdf